An	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
in	O
the	O
human	B-DNA
IL-2	I-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
promoter	I-DNA
is	O
a	O
composite	B-DNA
element	I-DNA
that	O
binds	O
Stat5	B-protein
,	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
and	O
a	O
GATA	B-protein
family	I-protein
protein	I-protein
.	O

Expression	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL-2	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
that	O
contains	O
both	O
consensus	B-DNA
and	I-DNA
non-consensus	I-DNA
GAS	I-DNA
motifs	I-DNA
,	O
two	O
putative	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
(	O
EBS	B-DNA
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
,	O
and	O
a	O
GATA	B-DNA
motif	I-DNA
,	O
which	O
overlaps	O
the	O
non-consensus	B-DNA
GAS	I-DNA
motif	I-DNA
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	B-protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	B-protein
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Multiple	O
factors	O
including	O
Stat5	B-protein
,	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
and	O
GATA	B-protein
family	I-protein
proteins	I-protein
bind	O
to	O
the	O
IL-2	B-DNA
response	I-DNA
element	I-DNA
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	B-protein
family	I-protein
protein	I-protein
binds	O
to	O
the	O
EBS	B-DNA
overlapping	O
the	O
consensus	B-DNA
GAS	I-DNA
motif	I-DNA
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	B-DNA
IL-2R	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Thus	O
,	O
IL-2	B-protein
-induced	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
requires	O
a	O
complex	B-DNA
upstream	I-DNA
element	I-DNA
,	O
which	O
appears	O
to	O
contain	O
binding	B-DNA
sites	I-DNA
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
regulatory	I-protein
factors	I-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.15	NULL
no.20	NULL
pp.5627-5635	NULL
,	NULL
1996	NULL
An	NULL
IL-2	NULL
response	NULL
element	NULL
in	NULL
the	NULL
human	NULL
IL-2	NULL
receptor	NULL
&	NULL
chain	NULL
promoter	NULL
is	NULL
a	NULL
composite	NULL
element	NULL
that	NULL
binds	NULL
Stat5	NULL
,	NULL
Elf-1	NULL
,	NULL
HMG-I	NULL
{	NULL
(	NULL
Y	NULL
)	NULL
and	NULL
a	NULL
GATA	NULL
family	NULL
protein	NULL
Susan	NULL
John	NULL
,	NULL
Christiane	NULL
M.Robbins	NULL
'	NULL
and	NULL
Warren	NULL
J.Leonard	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
National	NULL
Heart	NULL
,	NULL
Lung	NULL
and	NULL
Blood	NULL
Institute	NULL
,	NULL
Bldg	NULL
10	NULL
,	NULL
Rm	NULL
7N244	NULL
and	NULL
'Genome	NULL
Technology	NULL
Branch	NULL
,	NULL
National	NULL
Center	NULL
for	NULL
Genome	NULL
Research	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892-1674	NULL
,	NULL
USA	NULL
*Corresponding	NULL
author	NULL
Expression	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
&	NULL
chain	NULL
gene	NULL
is	NULL
potently	NULL
upregulated	NULL
by	NULL
its	NULL
own	NULL
ligand	NULL
,	NULL
IL-2	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
characterize	NULL
an	NULL
essential	NULL
upstream	NULL
IL-2	NULL
response	NULL
element	NULL
that	NULL
contains	NULL
both	NULL
consensus	NULL
and	NULL
non-consensus	NULL
GAS	NULL
motifs	NULL
,	NULL
two	NULL
putative	NULL
Ets	NULL
binding	NULL
sites	NULL
(	NULL
EBS	NULL
)	NULL
,	NULL
one	NULL
of	NULL
which	NULL
overlaps	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
,	NULL
and	NULL
a	NULL
GATA	NULL
motif	NULL
,	NULL
which	NULL
overlaps	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
although	NULL
the	NULL
individual	NULL
components	NULL
of	NULL
this	NULL
element	NULL
do	NULL
not	NULL
respond	NULL
to	NULL
IL-2	NULL
,	NULL
together	NULL
they	NULL
form	NULL
a	NULL
composite	NULL
element	NULL
capable	NULL
of	NULL
conferring	NULL
IL-2	NULL
responsiveness	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
.	NULL

Multiple	NULL
factors	NULL
including	NULL
Stat5	NULL
,	NULL
Elf-1	NULL
,	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
and	NULL
GATA	NULL
family	NULL
proteins	NULL
bind	NULL
to	NULL
the	NULL
IL-2	NULL
response	NULL
element	NULL
and	NULL
mutation	NULL
of	NULL
any	NULL
one	NULL
of	NULL
these	NULL
binding	NULL
sites	NULL
diminishes	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
element	NULL
.	NULL

An	NULL
unidentified	NULL
Ets	NULL
family	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
EBS	NULL
overlapping	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
and	NULL
appears	NULL
to	NULL
negatively	NULL
regulate	NULL
the	NULL
human	NULL
IL-2Ra	NULL
promoter	NULL
.	NULL

Thus	NULL
,	NULL
IL-2-induced	NULL
IL-2Ro	NULL
promoter	NULL
activity	NULL
requires	NULL
a	NULL
complex	NULL
upstream	NULL
element	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
contain	NULL
binding	NULL
sites	NULL
for	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
factors	NULL
.	NULL

Keywords	NULL
:	NULL
Elf-1/GATA/HMG-I	NULL
(	NULL
Y	NULL
)	NULL
/IL-2	NULL
receptor/STAT	NULL
Introduction	NULL
There	NULL
are	NULL
three	NULL
classes	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
proteins	NULL
.	NULL

High	NULL
affinity	NULL
receptors	NULL
(	NULL
K4	NULL
~10-	NULL
``	NULL
'	NULL
M	NULL
)	NULL
contain	NULL
the	NULL
x	NULL
,	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
;	NULL
intermediate	NULL
affinity	NULL
IL-2Rs	NULL
(	NULL
K	NULL
,	NULL
~10°	NULL
M	NULL
)	NULL
contain	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
;	NULL
and	NULL
low	NULL
affinity	NULL
receptors	NULL
(	NULL
K	NULL
,	NULL
~10~	NULL
M	NULL
)	NULL
contain	NULL
only	NULL
the	NULL
&	NULL
chain	NULL
(	NULL
Leonard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Sugamura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Taniguchi	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
intermediate	NULL
and	NULL
high	NULL
affinity	NULL
forms	NULL
are	NULL
capable	NULL
of	NULL
transducing	NULL
mitogenic	NULL
signals	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
,	NULL
whereas	NULL
low	NULL
affinity	NULL
receptors	NULL
are	NULL
not	NULL
,	NULL
indicating	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
(	NULL
reviewed	NULL
in	NULL
Leonard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Sugamura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Taniguchi	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Although	NULL
IL-is	NULL
not	NULL
required	NULL
for	NULL
IL-2-induced	NULL
signaling	NULL
,	NULL
its	NULL
essential	NULL
role	NULL
is	NULL
underscored	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
mice	NULL
lacking	NULL
expression	NULL
of	NULL
this	NULL
gene	NULL
develop	NULL
severe	NULL
autoimmunity	NULL
and	NULL
die	NULL
at	NULL
a	NULL
young	NULL
age	NULL
(	NULL
Willerford	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
IL-2R	NULL
«	NULL
is	NULL
presumably	NULL
based	NULL
on	NULL
the	NULL
need	NULL
to	NULL
achieve	NULL
high	NULL
affinity	NULL
receptors	NULL
in	NULL
order	NULL
to	NULL
bind	NULL
the	NULL
relatively	NULL
low	NULL
concentrations	NULL
of	NULL
IL-2	NULL
that	NULL
are	NULL
physiologically	NULL
produced	NULL
.	NULL

The	NULL
IL-2Ro	NULL
gene	NULL
is	NULL
potently	NULL
induced	NULL
by	NULL
antigens	NULL
and	NULL
mitogens	NULL
,	NULL
the	NULL
transactivator	NULL
protein	NULL
of	NULL
HTLV-I	NULL
and	NULL
certain	NULL
cytokines	NULL
,	NULL
including	NULL
IL-2	NULL
(	NULL
Depper	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Inoue	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Cross	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Maruyama	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Siegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Siekevitz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
IL-2R	NULL
&	NULL
promoter	NULL
contains	NULL
two	NULL
important	NULL
positive	NULL
regulatory	NULL
regions	NULL
,	NULL
PRRI	NULL
(	NULL
-276	NULL
to	NULL
-244	NULL
)	NULL
(	NULL
Bohnlein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Leung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Ballard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Cross	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Lowenthal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Roman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Toledano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Algarte	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
PRRII	NULL
(	NULL
-137	NULL
to	NULL
-64	NULL
)	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
that	NULL
together	NULL
are	NULL
required	NULL
for	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
the	NULL
IL-2Ra	NULL
gene	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

PRRI	NULL
binds	NULL
to	NULL
NF-KB1	NULL
,	NULL
c-Rel	NULL
and	NULL
serum	NULL
response	NULL
factor	NULL
(	NULL
SRF	NULL
)	NULL
,	NULL
while	NULL
PRRII	NULL
binds	NULL
the	NULL
lymphoid/myeloid-specific	NULL
Ets	NULL
family	NULL
protein	NULL
,	NULL
Elf-1	NULL
,	NULL
and	NULL
the	NULL
high	NULL
mobility	NULL
group	NULL
proteins	NULL
,	NULL
HMG-I	NULL
(	NULL
¥	NULL
)	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Intramolecular	NULL
interactions	NULL
between	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
PRRI	NULL
and	NULL
PRRII	NULL
appear	NULL
to	NULL
result	NULL
in	NULL
a	NULL
highly-ordered	NULL
stereospecific	NULL
complex	NULL
that	NULL
regulates	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-2Ra	NULL
promoter	NULL
upon	NULL
mitogenic	NULL
stimulation	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Although	NULL
IL-2	NULL
potently	NULL
induces	NULL
IL-2R	NULL
«	NULL
,	NULL
in	NULL
transfected	NULL
YT	NULL
cells	NULL
,	NULL
it	NULL
did	NULL
not	NULL
induce	NULL
IL-2R	NULL
&	NULL
-CAT	NULL
reporter	NULL
constructs	NULL
spanning	NULL
PRRI	NULL
and	NULL
PRRII	NULL
.	NULL

In	NULL
the	NULL
murine	NULL
IL-2Ra	NULL
&	NULL
chain	NULL
gene	NULL
,	NULL
an	NULL
IL-2	NULL
response	NULL
element	NULL
is	NULL
located	NULL
~1.3	NULL
kb	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
Sperisen	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
now	NULL
characterize	NULL
a	NULL
similar	NULL
IL-2	NULL
response	NULL
element	NULL
(	NULL
denoted	NULL
PRRIII	NULL
)	NULL
in	NULL
the	NULL
human	NULL
IL-2Ra	NULL
promoter	NULL
,	NULL
located	NULL
~3.7	NULL
kb	NULL
upstream	NULL
of	NULL
the	NULL
initiation	NULL
of	NULL
transcription	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
PRRIII	NULL
is	NULL
a	NULL
complex	NULL
element	NULL
capable	NULL
of	NULL
conferring	NULL
IL-2	NULL
inducibility	NULL
to	NULL
a	NULL
minimal	NULL
heterologous	NULL
promoter	NULL
.	NULL

It	NULL
contains	NULL
both	NULL
consensus	NULL
and	NULL
non-consensus	NULL
GAS	NULL
motifs	NULL
and	NULL
two	NULL
distinct	NULL
Ets	NULL
binding	NULL
sites	NULL
(	NULL
EBSs	NULL
)	NULL
,	NULL
one	NULL
of	NULL
which	NULL
overlaps	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
,	NULL
and	NULL
an	NULL
important	NULL
GATA	NULL
motif	NULL
,	NULL
which	NULL
overlaps	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
.	NULL

By	NULL
performing	NULL
binding	NULL
studies	NULL
and	NULL
mutational	NULL
analysis	NULL
,	NULL
we	NULL
clarify	NULL
how	NULL
the	NULL
components	NULL
of	NULL
PRRIII	NULL
cooperate	NULL
to	NULL
form	NULL
a	NULL
composite	NULL
unit	NULL
that	NULL
regulates	NULL
IL-2-induced	NULL
IL-2R	NULL
«	NULL
promoter	NULL
activity	NULL
.	NULL

Results	NULL
Identification	NULL
of	NULL
a	NULL
sequence	NULL
in	NULL
the	NULL
human	NULL
IL-2Ra	NULL
promoter	NULL
similar	NULL
to	NULL
the	NULL
murine	NULL
IL-2	NULL
response	NULL
element	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
two	NULL
positive	NULL
regulatory	NULL
ele-ments	NULL
,	NULL
PRRI	NULL
and	NULL
PRRII	NULL
,	NULL
are	NULL
essential	NULL
for	NULL
the	NULL
mitogen-induced	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
IL-2Ra	NULL
&	NULL
promoter	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
PRRI	NULL
and	NULL
PRRII	NULL
(	NULL
-472	NULL
to	NULL
+109	NULL
IL-2R	NULL
&	NULL
-CAT	NULL
)	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
IL-2	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

In	NULL
the	NULL
murine	NULL
IL-2R	NULL
«	NULL
&	NULL
promoter	NULL
,	NULL
an	NULL
IL-2	NULL
response	NULL
element	NULL
was	NULL
identified	NULL
between	NULL
nucleotides	NULL
-1376	NULL
and	NULL
-1304	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
Sperisen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
human	NULL
IL-2Ro	NULL
promoter	NULL
revealed	NULL
that	NULL
a	NULL
5627	NULL
S	NULL
$	NULL
.John	NULL
,	NULL
C.M.Robbins	NULL
and	NULL
W.J.Leonard	NULL
similar	NULL
sequence	NULL
was	NULL
located	NULL
between	NULL
nucleotides	NULL
-3780	NULL
and	NULL
-3703	NULL
(	NULL
PRRIII	NULL
,	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Analogous	NULL
to	NULL
the	NULL
murine	NULL
sequence	NULL
,	NULL
this	NULL
human	NULL
sequence	NULL
contains	NULL
a	NULL
consensus	NULL
GAS	NULL
motif	NULL
(	NULL
GAS-c	NULL
)	NULL
,	NULL
a	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
(	NULL
GAS-n	NULL
)	NULL
,	NULL
a	NULL
putative	NULL
GATA	NULL
motif	NULL
and	NULL
an	NULL
'Ets	NULL
'	NULL
motif	NULL
(	NULL
EBS	NULL
)	NULL
,	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Unlike	NULL
the	NULL
murine	NULL
consensus	NULL
GAS	NULL
motif	NULL
sequence	NULL
(	NULL
TTCTGAGAA	NULL
)	NULL
,	NULL
the	NULL
human	NULL
sequence	NULL
contains	NULL
an	NULL
overlapping	NULL
GGAA	NULL
Ets	NULL
motif	NULL
(	NULL
TTCTAGGAA	NULL
,	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
PRRIII	NULL
was	NULL
sufficient	NULL
to	NULL
confer	NULL
IL-2	NULL
inducibility	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
,	NULL
the	NULL
full-length	NULL
PRRIII	NULL
oligonucleotide	NULL
(	NULL
-3780	NULL
to	NULL
-3703	NULL
)	NULL
and	NULL
each	NULL
of	NULL
its	NULL
individual	NULL
sub-elements	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
a	NULL
minimal	NULL
TK	NULL
promoter	NULL
in	NULL
pBLCAT2	NULL
and	NULL
the	NULL
resulting	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
YT	NULL
natural	NULL
killer-like	NULL
cells	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

Only	NULL
the	NULL
full-length	NULL
PRRIII	NULL
oligonucleotide	NULL
conferred	NULL
maximal	NULL
IL-2	NULL
inducibility	NULL
to	NULL
the	NULL
TK	NULL
promoter	NULL
,	NULL
suggesting	NULL
that	NULL
PRRIII	NULL
functions	NULL
as	NULL
a	NULL
composite	NULL
element	NULL
.	NULL

Signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
,	NULL
Ets	NULL
and	NULL
GATA	NULL
family	NULL
protein	NULL
recognition	NULL
sites	NULL
are	NULL
contacted	NULL
in	NULL
PRRIll	NULL
To	NULL
characterize	NULL
the	NULL
range	NULL
of	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
PRRIII	NULL
,	NULL
we	NULL
performed	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
with	NULL
a	NULL
PRRIII	NULL
oligonucleotide	NULL
and	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
PBL	NULL
that	NULL
were	NULL
preactivated	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
,	NULL
rested	NULL
,	NULL
and	NULL
then	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

We	NULL
used	NULL
preactivated	NULL
PBL	NULL
rather	NULL
than	NULL
freshly	NULL
isolated	NULL
PBL	NULL
for	NULL
this	NULL
study	NULL
in	NULL
order	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
cells	NULL
were	NULL
primed	NULL
to	NULL
be	NULL
maximally	NULL
responsive	NULL
to	NULL
IL-2	NULL
treatment	NULL
.	NULL

EMSAs	NULL
with	NULL
the	NULL
full-length	NULL
PRRIII	NULL
probe	NULL
(	NULL
-3780	NULL
to	NULL
-3703	NULL
)	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
three	NULL
major	NULL
complexes	NULL
(	NULL
C1	NULL
,	NULL
C2	NULL
and	NULL
C3	NULL
)	NULL
in	NULL
uninduced	NULL
extracts	NULL
(	NULL
Figure	NULL
2A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Complex	NULL
C3	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
degradation	NULL
product	NULL
of	NULL
C2	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Upon	NULL
stimulation	NULL
with	NULL
IL-2	NULL
,	NULL
a	NULL
new	NULL
complex	NULL
(	NULL
C4	NULL
)	NULL
was	NULL
formed	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
cycloheximide	NULL
did	NULL
not	NULL
prevent	NULL
formation	NULL
of	NULL
complex	NULL
C4	NULL
,	NULL
indicating	NULL
that	NULL
its	NULL
formation	NULL
did	NULL
not	NULL
depend	NULL
on	NULL
new	NULL
protein	NULL
synthesis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
a	NULL
finding	NULL
consistent	NULL
with	NULL
our	NULL
ability	NULL
to	NULL
detect	NULL
complex	NULL
C4	NULL
within	NULL
30	NULL
min	NULL
of	NULL
IL-2	NULL
stimulation	NULL
.	NULL

Formation	NULL
of	NULL
complexes	NULL
C1-C4	NULL
was	NULL
specific	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
unlabeled	NULL
excess	NULL
PRRIII	NULL
oligonucleotide	NULL
to	NULL
compete	NULL
the	NULL
binding	NULL
activities	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
YT	NULL
cells	NULL
that	NULL
were	NULL
not	NULL
stimulated	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
nucleotide	NULL
sequences	NULL
contacted	NULL
by	NULL
complexes	NULL
C1	NULL
,	NULL
C2	NULL
and	NULL
C4	NULL
,	NULL
we	NULL
performed	NULL
methylation	NULL
interference	NULL
analyses	NULL
using	NULL
the	NULL
full-length	NULL
PRRIII	NULL
oligonucleotide	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
preactivated	NULL
PBL	NULL
that	NULL
were	NULL
not	NULL
induced	NULL
or	NULL
induced	NULL
with	NULL
IL-2	NULL
(	NULL
Figure	NULL
2B	NULL
and	NULL
summarized	NULL
in	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

In	NULL
complex	NULL
C1	NULL
,	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
strongly	NULL
contacted	NULL
the	NULL
Gs	NULL
at	NULL
-3765	NULL
,	NULL
-3764	NULL
,	NULL
-3725	NULL
and	NULL
-3724	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
both	NULL
pairs	NULL
of	NULL
Gs	NULL
are	NULL
contained	NULL
within	NULL
Ets	NULL
binding	NULL
sites	NULL
suggested	NULL
that	NULL
C1	NULL
contains	NULL
Ets	NULL
family	NULL
proteins	NULL
.	NULL

Protein	NULL
(	NULL
s	NULL
)	NULL
in	NULL
complex	NULL
C2	NULL
also	NULL
contacted	NULL
these	NULL
same	NULL
nucleotides	NULL
albeit	NULL
somewhat	NULL
less	NULL
strongly	NULL
than	NULL
those	NULL
in	NULL
C1	NULL
(	NULL
lanes	NULL
5-8	NULL
and	NULL
9-12	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
C2	NULL
may	NULL
also	NULL
contains	NULL
Ets	NULL
family	NULL
proteins	NULL
.	NULL

The	NULL
IL-2-inducible	NULL
complex	NULL
(	NULL
C4	NULL
)	NULL
strongly	NULL
contacted	NULL
G	NULL
nucleotides	NULL
at	NULL
-3768	NULL
,	NULL
-3765	NULL
,	NULL
-3764	NULL
,	NULL
-3761	NULL
and	NULL
-3748	NULL
within	NULL
the	NULL
two	NULL
GAS	NULL
motifs	NULL
,	NULL
the	NULL
G	NULL
nucleotide	NULL
at	NULL
-3746	NULL
of	NULL
the	NULL
putative	NULL
GATA	NULL
motif	NULL
and	NULL
the	NULL
G	NULL
at	NULL
-3739	NULL
,	NULL
immediately	NULL
5628	NULL
following	NULL
the	NULL
putative	NULL
GATA	NULL
motif	NULL
;	NULL
in	NULL
addition	NULL
,	NULL
the	NULL
Gs	NULL
of	NULL
the	NULL
Ets	NULL
motif	NULL
located	NULL
at	NULL
nucleotides	NULL
-3725	NULL
and	NULL
-3724	NULL
were	NULL
also	NULL
weakly	NULL
protected	NULL
(	NULL
lanes	NULL
13-16	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Ets	NULL
family	NULL
proteins	NULL
in	NULL
preactivated	NULL
PBL	NULL
bind	NULL
to	NULL
PRRIII	NULL
and	NULL
that	NULL
upon	NULL
stimulation	NULL
of	NULL
these	NULL
cells	NULL
with	NULL
IL-2	NULL
,	NULL
a	NULL
new	NULL
complex	NULL
is	NULL
formed	NULL
that	NULL
may	NULL
contain	NULL
STAT	NULL
and	NULL
GATA	NULL
family	NULL
proteins	NULL
in	NULL
addition	NULL
to	NULL
Ets	NULL
family	NULL
proteins	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
with	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
PRRIII	NULL
oligonucleotides	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
to	NULL
determine	NULL
how	NULL
each	NULL
binding	NULL
site	NULL
in	NULL
PRRIII	NULL
contributed	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
C1	NULL
,	NULL
C2	NULL
,	NULL
C3	NULL
and	NULL
C4	NULL
.	NULL

Binding	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
probe	NULL
is	NULL
shown	NULL
in	NULL
Figure	NULL
3B	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
,	NULL
so	NULL
that	NULL
the	NULL
overlapping	NULL
Ets	NULL
motif	NULL
was	NULL
left	NULL
intact	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
;	NULL
mutant	NULL
M1.0	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
C4	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
mutant	NULL
exhibited	NULL
an	NULL
increase	NULL
in	NULL
C1	NULL
and	NULL
also	NULL
formed	NULL
a	NULL
new	NULL
complex	NULL
with	NULL
both	NULL
uninduced	NULL
and	NULL
IL-2-induced	NULL
extracts	NULL
.	NULL

Selective	NULL
mutation	NULL
of	NULL
the	NULL
overlapping	NULL
Ets	NULL
motif	NULL
(	NULL
leaving	NULL
intact	NULL
the	NULL
TTCXXX-GAA	NULL
consensus	NULL
GAS	NULL
motif	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
C1	NULL
,	NULL
a	NULL
decrease	NULL
in	NULL
C2	NULL
and	NULL
C3	NULL
and	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
C4	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
;	NULL
mutant	NULL
M1.1	NULL
)	NULL
,	NULL
although	NULL
a	NULL
low	NULL
level	NULL
of	NULL
C4	NULL
was	NULL
still	NULL
visible	NULL
on	NULL
a	NULL
longer	NULL
exposure	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Simultaneous	NULL
mutation	NULL
of	NULL
both	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
and	NULL
the	NULL
overlapping	NULL
EBS	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
;	NULL
mutant	NULL
M1.2	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
total	NULL
loss	NULL
of	NULL
C1	NULL
and	NULL
C4	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
C2	NULL
and	NULL
C3	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
and	NULL
the	NULL
'T	NULL
in	NULL
the	NULL
associated	NULL
GATA	NULL
motif	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
;	NULL
mutant	NULL
M2.1	NULL
)	NULL
or	NULL
of	NULL
only	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
(	NULL
from	NULL
TTCTGATAA	NULL
to	NULL
TTGTGATAA	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
eliminated	NULL
only	NULL
complex	NULL
C4	NULL
,	NULL
while	NULL
mutation	NULL
of	NULL
only	NULL
the	NULL
'T	NULL
in	NULL
the	NULL
GATA	NULL
motif	NULL
still	NULL
allowed	NULL
C4	NULL
formation	NULL
albeit	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
;	NULL
mutant	NULL
M2.2	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
EBS	NULL
at	NULL
nucleotides	NULL
-3724	NULL
and	NULL
-3725	NULL
(	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
;	NULL
mutant	NULL
M3	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
C1	NULL
,	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
C2	NULL
and	NULL
C3	NULL
and	NULL
a	NULL
more	NULL
modest	NULL
decrease	NULL
in	NULL
C4	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
this	NULL
downstream	NULL
Ets	NULL
motif	NULL
is	NULL
required	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
C1	NULL
.	NULL

Furthermore	NULL
,	NULL
they	NULL
suggest	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
C4	NULL
is	NULL
dependent	NULL
on	NULL
multiple	NULL
sites	NULL
.	NULL

Mutation	NULL
of	NULL
both	NULL
GAS	NULL
motifs	NULL
resulted	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
C1	NULL
and	NULL
C4	NULL
(	NULL
lanes	NULL
15	NULL
and	NULL
16	NULL
;	NULL
mutant	NULL
MS	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
mutation	NULL
of	NULL
all	NULL
three	NULL
protein	NULL
binding	NULL
sites	NULL
(	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
;	NULL
mutant	NULL
M6	NULL
)	NULL
,	NULL
resulted	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
C1	NULL
,	NULL
C2	NULL
(	NULL
C3	NULL
)	NULL
and	NULL
C4	NULL
.	NULL

These	NULL
data	NULL
(	NULL
summarized	NULL
in	NULL
Figure	NULL
3C	NULL
)	NULL
suggest	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
C4	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
consensus	NULL
and	NULL
non-consensus	NULL
GAS	NULL
motifs	NULL
,	NULL
with	NULL
their	NULL
overlapping	NULL
EBS	NULL
and	NULL
GATA	NULL
motifs	NULL
respectively	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
on	NULL
the	NULL
downstream	NULL
EBS	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
formation	NULL
of	NULL
complex	NULL
C1	NULL
depends	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
intact	NULL
Ets	NULL
binding	NULL
sites	NULL
.	NULL

Elf-1	NULL
,	NULL
Stat5	NULL
and	NULL
a	NULL
GATA	NULL
protein	NULL
can	NULL
bind	NULL
to	NULL
PRRII	NULL
Next	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
proteins	NULL
contained	NULL
within	NULL
each	NULL
complex	NULL
.	NULL

Since	NULL
IL-2	NULL
potently	NULL
activates	NULL
both	NULL
StatSA	NULL
and	NULL
Stat5B	NULL
(	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
we	NULL
used	NULL
specific	NULL
antisera	NULL
in	NULL
antibody	NULL
supershift	NULL
experiments	NULL
and	NULL
found	NULL
that	NULL
both	NULL
StatSA	NULL
and	NULL
StatSB	NULL
antibodies	NULL
affected	NULL
complex	NULL
C4	NULL
,	NULL
suggesting	NULL
that	NULL
both	NULL
StatSA	NULL
and	NULL
Stat5B	NULL
were	NULL
present	NULL
in	NULL
this	NULL
complex	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
antibodies	NULL
to	NULL
Stat3	NULL
and	NULL
Statl	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
methylation	NULL
interference	NULL
analysis	NULL
suggested	NULL
that	NULL
C1	NULL
,	NULL
C2	NULL
and	NULL
C4	NULL
contained	NULL
Ets	NULL
family	NULL
proteins	NULL
.	NULL

Since	NULL
a	NULL
low	NULL
affinity	NULL
Elf-1	NULL
site	NULL
in	NULL
PRRII	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
vital	NULL
for	NULL
IL-2Ra	NULL
&	NULL
transcription	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
,	NULL
1996	NULL
)	NULL
,	NULL
we	NULL
IL-2	NULL
response	NULL
element	NULL
in	NULL
human	NULL
IL-2R	NULL
«	NULL
promoter	NULL
~4103	NULL
AGA	NULL
TCTTATICTG	NULL
TTTTICGAGG	NULL
-4081	NULL
-4080	NULL
TCCACCTGAC	NULL
TCTGAATCCA	NULL
GCTGATATTT	NULL
CTGCecTTAG	NULL
CTICTACCCC	NULL
TCTCTACTTC	NULL
TGGTTAACTA	NULL
TGGACCACAC	NULL
-4001	NULL
4000	NULL
TCTGCTTCCT	NULL
CAGGAACCAC	NULL
CTACCAAGGC	NULL
CGTATCCATC	NULL
CTTCAAGGAC	NULL
AMTACGTGGG	NULL
CCTPTCCTGA	NULL
TCACATCAGC	NULL
-3921	NULL
-3920	NULL
TCRACAACTT	NULL
TTCCCTCCTA	NULL
CATTTCAATT	NULL
GCTCTTCTTA	NULL
CCATAATCAT	NULL
TAGTATTCAC	NULL
CCCACTGTAC	NULL
GTCTAGAAAG	NULL
-3841	NULL
Consensus	NULL
GAS	NULL
motif	NULL
-3840	NULL
AARAGTGGTCT	NULL
TAAACCTAAG	NULL
GGAAGGCAGT	NULL
CTAGGTCAGA	NULL
AATTTGTTGT	NULL
CCoctorTct	NULL
[	NULL
GAGCAGTTIC	NULL
TromaceAmc	NULL
-3761	NULL
prailt	NULL
Non-consensus	NULL
Ets	NULL
binding	NULL
GAS	NULL
motif	NULL
site	NULL
-3760	NULL
TACCAAACAT	NULL
TTCTGATAAT	NULL
AGAATIGAGC	NULL
AATPRCCIGA	NULL
TGAAGTGAGA	NULL
CTCAGCT	NULL
To	NULL
acrerreace	NULL
cecrerceer	NULL
-3681	NULL
-~3680	NULL
CGATGAACCT	NULL
AGTTACTTTT	NULL
AACCAAATGT	NULL
TCCTTTCTTG	NULL
AACTTGTTCC	NULL
TPTCTTGAAC	NULL
TTAATCTACC	NULL
AATGTTATCT	NULL
-360	NULL
%	NULL
-3600	NULL
AGATAACTTT	NULL
CCTCAAAAAA	NULL
AAMAAAAAAA	NULL
AAMAAMCCCT	NULL
CTACTAGGAA	NULL
AGAAMTCTTT	NULL
GAACCGGACT	NULL
TATTGGAAAT	NULL
-3521	NULL
-3520	NULL
TACCTCCTTG	NULL
CAGCAGGTTT	NULL
GAAACAAAAC	NULL
TTTGAATTTG	NULL
CCTCACAAAG	NULL
AATTTGTCTG	NULL
AAACTGCTTT	NULL
AGTATATGCT	NULL
-3441	NULL
-3440	NULL
AGTTATATTT	NULL
GTATGCACAT	NULL
GTGGCTTCAT	NULL
ACATAGTGGT	NULL
TGGACACCCA	NULL
TATGTGTTAT	NULL
GCACTTTGIT	NULL
AGGTGACGTA	NULL
-3361	NULL
~3360	NULL
AGTTCACAGA	NULL
TAAACTGGAC	NULL
ATAGGGCTAT	NULL
CCTCTAGAGG	NULL
CCCACAGTTT	NULL
GACACCTTAA	NULL
CCTGAGATCC	NULL
TTGGACCTTT	NULL
-3261	NULL
~3280	NULL
GAAGTTCAGA	NULL
GTGCCCACAA	NULL
CCGCTGGGTG	NULL
TGGTGGcTca	NULL
CACTPTGTAAT	NULL
CCcAGTACTC	NULL
TGCAGeceTe	NULL
-3201	NULL
-3200	NULL
ATCGCTTGAG	NULL
TCCAGGAGTC	NULL
TGAGACCAGC	NULL
CTGGGCAACA	NULL
TGACAAAACC	NULL
CCATCTCTAC	NULL
AAAAATTACA	NULL
AAMAAAATTA	NULL
-3121	NULL
-3120	NULL
GCCAGGCCTG	NULL
GTGGTGCATG	NULL
CAGTTACTTG	NULL
AGAGGCTGAA	NULL
GTeGGAGGAT	NULL
CACTTGAGTC	NULL
AAGGAGGTAG	NULL
-3041	NULL
~3040	NULL
AGGCTGCAGT	NULL
GAGTTGAGAT	NULL
GGCAACACTG	NULL
CACTCCAGAA	NULL
ACCCCATCTC	NULL
AAACAAAACG	NULL
GAGCAAAACA	NULL
AAACAAACTG	NULL
-2961	NULL
~2960	NULL
CCCATAATGC	NULL
TCCTGAMACT	NULL
TCCTACGGAT	NULL
TTATCCAGAG	NULL
TATGTGCTGA	NULL
TGTGCATTTT	NULL
TTCCAAGGAG	NULL
CGAAACCAAA	NULL
-2881	NULL
~2880	NULL
GGTTCTATCA	NULL
AATTAAGAAA	NULL
AGAGTTTTTA	NULL
CCATTGTGGA	NULL
AGACAGTATG	NULL
GCGATTCCTC	NULL
AAGCATCTAA	NULL
AATCAGAAAT	NULL
-2801	NULL
-~2800	NULL
ACCATTTGAC	NULL
CCAGCAATCC	NULL
TATTACTGGG	NULL
TATATACCCA	NULL
AAGGAATAGA	NULL
AATCATTCTA	NULL
CTATAAAGTC	NULL
ACATGCACCC	NULL
-2721	NULL
-2720	NULL
GTATGTTTAT	NULL
TGCAGCACTA	NULL
TTTACAATAG	NULL
CAAAATGGAA	NULL
CCAACTGAAA	NULL
TGCCCATCAA	NULL
TGAGACTAGA	NULL
TAAMGAAAAT	NULL
-2641	NULL
-2640	NULL
GTGATACATA	NULL
TACACCATGG	NULL
AATACTATGC	NULL
AGCCATGAAA	NULL
AGGAATGAGA	NULL
TCATCTCCTT	NULL
GGCAGGGACA	NULL
TGGATGAAGC	NULL
-2561	NULL
-2560	NULL
TGGAAGCCAT	NULL
TATCCTCAGC	NULL
AMACTRACAC	NULL
AGGAACAGAA	NULL
AACCAAATGC	NULL
CGCATGTTCT	NULL
CACTCATAAG	NULL
TGGGAGPTGA	NULL
-2481	NULL
-2480	NULL
ACAATGACAG	NULL
CACATAGACA	NULL
TAGGGAGGGG	NULL
AACATCACAC	NULL
GCCAGGGCCT	NULL
GcTecacest	NULL
ceccectces	NULL
CTorcacces	NULL
-2401	NULL
AGGCAACTTA	NULL
GAAGACAGGT	NULL
GAGTAGGTGC	NULL
AGCAGACCAC	NULL
CATGGCGCAC	NULL
TTATACCTAT	NULL
GTAACCAACC	NULL
TGCACGTTCT	NULL
-2321	NULL
-2320	NULL
ACACATGTAT	NULL
CCTGGAACTT	NULL
AAATTAAAAA	NULL
CAAAAAAGAG	NULL
TTTTTAATCC	NULL
AAAAAAGATT	NULL
AMCAGCAACT	NULL
AGAAGAAAGA	NULL
-2241	NULL
~2240	NULL
AAMGAGATATA	NULL
AMCAGTGAAT	NULL
TGCAATGCAG	NULL
CACGGCAGGT	NULL
GTTATGATGG	NULL
AGTAGAAAGG	NULL
ACTGGAAAAG	NULL
GCCTCCTGGA	NULL
-2161	NULL
-2160	NULL
GGAAGGGACA	NULL
CTCAAGTGTC	NULL
TPTCCATTTC	NULL
ACCTGTAAAC	NULL
TCATTAAGGG	NULL
CAAAAGCTTT	NULL
GCTACAGCTT	NULL
CAGTATGAGA	NULL
-2081	NULL
-2080	NULL
TCCTGGGCAA	NULL
TCCGTGACAA	NULL
AMTGGGTCTG	NULL
CTTTTGCACC	NULL
CCCAACTTCT	NULL
TCTCACATCC	NULL
CTGCATCGTS	NULL
CCATGCAGCA	NULL
-2001	NULL
TCAACTGGAA	NULL
ACCTCAGCAT	NULL
CAGCAAACGA	NULL
CGACAGAGCG	NULL
TTCATCCGTA	NULL
AGGTGAACCA	NULL
GAAAAGCCAG	NULL
TTCAATGACT	NULL
-192	NULL
:	NULL
-~1920	NULL
TGTTTAACCA	NULL
TGGTCCATCT	NULL
CAGAACCAAG	NULL
AGTTGGGCCT	NULL
CTTATPTACC	NULL
AGAAAAATTG	NULL
TGOGGGCTTT	NULL
GTGATATGGc	NULL
-184	NULL
:	NULL
-~1840	NULL
TTTAAAAAAA	NULL
TCTTGTAATT	NULL
GCCAGGCGTG	NULL
GTGGCTCACA	NULL
CCTGTAATCC	NULL
CAGCACTTTG	NULL
GGAGGCCGAG	NULL
GTGGGTGAAT	NULL
-176	NULL
:	NULL
-1760	NULL
CGCCTAAGGT	NULL
CAGGAGTTCG	NULL
AGACCAGCCT	NULL
GACCAACATG	NULL
GTGAAACTCC	NULL
GTCTCTACTA	NULL
AAAATACAAX	NULL
AACTAGCTGG	NULL
-1681	NULL
-~1680	NULL
ATGTGGTGAC	NULL
GCGTGCCTGT	NULL
AATCCTAGCT	NULL
ACTCAGGAGG	NULL
CTGACGCAGG	NULL
AGAATCACTT	NULL
CAACCTGGGA	NULL
GGCAGAGGTT	NULL
-1601	NULL
-~1600	NULL
GCAGTGAGCC	NULL
AAGATTGTGC	NULL
CATTGCGCTC	NULL
CAMAMAAAAA	NULL
AAAAAAAAAG	NULL
ACATTAACAT	NULL
AAATTTAAAT	NULL
ATTTTATAAT	NULL
-1522	NULL
-~1520	NULL
GACAATCCAC	NULL
ATTAACTACT	NULL
TAAAGCATAA	NULL
GCTATTTTCC	NULL
AGGAGAGGCA	NULL
GCAMGTGCAT	NULL
TCTACTCCCA	NULL
TGcccAMGAA	NULL
-1441	NULL
~1440	NULL
GAAAGGAGCG	NULL
TGACTTTGGT	NULL
GGGAGTACTA	NULL
GGAGTTTCTA	NULL
CIGGAGCACT	NULL
TGCCCGCAGA	NULL
GTGAGAAACG	NULL
TTCCTAGAGA	NULL
-1361	NULL
-~1360	NULL
GGAAGTTATA	NULL
CCTGCTGTGG	NULL
AATTTAAGAG	NULL
AATCTTGTCA	NULL
TATPPTGACA	NULL
AGTTTTTTGA	NULL
GATGGAAGTC	NULL
TCACTCTGTC	NULL
-1231	NULL
-~1280	NULL
CCCCAGGCTG	NULL
GAGTGCAGTG	NULL
GCECAATCTC	NULL
AGCTCACTGC	NULL
AGCCTGcAce	NULL
Tecrcooctc	NULL
CAGCTATTCT	NULL
CTIGTCrcAG	NULL
-1201	NULL
~1200	NULL
CCTCCTGAGT	NULL
AACTGGGATT	NULL
ACAGGCGece	NULL
GCCACTACGC	NULL
CTGGCTAATT	NULL
TTTGTATTTT	NULL
TAGTAGAMAT	NULL
CGGGTPPTAC	NULL
-l12l	NULL
-1120	NULL
CATGTTGGCC	NULL
AGACTGGTCT	NULL
CAAACTCCCG	NULL
ACCTCAGGTG	NULL
ATCTGCCTGC	NULL
CTCAGCCTCC	NULL
CAAAGTGCTG	NULL
GAATTACAGG	NULL
-1041	NULL
-1040	NULL
CGTGTGCCAC	NULL
TGCGCCTeGc	NULL
TAATTTPTTT	NULL
TPITTITTIT	NULL
TPFPAGTAGA	NULL
GACGGTGGTT	NULL
TCACCATGTC	NULL
ATCCAGGCTG	NULL
-961	NULL
-960	NULL
GTCTCAAACT	NULL
CCTGACCTCA	NULL
GGTGATCCAC	NULL
CCACCTTGGT	NULL
CTACCAAAGT	NULL
GCTCGGATTA	NULL
CAGGCATGAG	NULL
CCACCAGGCC	NULL
-881	NULL
-~880	NULL
CAGTCAACGT	NULL
GATGTGTTTT	NULL
GGAACCCTCA	NULL
ATTCCTTGGC	NULL
TIGCCCGGAG	NULL
GGTTPTCTTT	NULL
TTGTTAATAT	NULL
-801	NULL
-800	NULL
TPTCTAGTAT	NULL
TTAMAAAATT	NULL
CTGTTTTGCT	NULL
CTAACTATGC	NULL
AATGGCTTTA	NULL
AGTCTTAGAC	NULL
AAATTTCCAG	NULL
GGAGCAAAAC	NULL
-721	NULL
-720	NULL
ACACTCAACC	NULL
AMTTTCATAA	NULL
TAMTCAGAAG	NULL
AGAGCTCTGA	NULL
TCAATAAATA	NULL
AGCAAGACTG	NULL
AMTTTTACAA	NULL
AATAATCCAA	NULL
-641	NULL
~640	NULL
AGTTTAAAAC	NULL
CAAMGCCCAC	NULL
TTTPTGCATG	NULL
ATCCTTTAAG	NULL
AGAAAGAAAT	NULL
CTOGAAGCAA	NULL
AACACCTTAT	NULL
AAAATGACAA	NULL
-561	NULL
-560	NULL
TGCACTTTCA	NULL
GGAGCCCAGA	NULL
GCACTGTGCT	NULL
CAAATGATGA	NULL
TGOCTACTAC	NULL
AGGTTATAAG	NULL
CCTTGGGGAA	NULL
TTATTTATGA	NULL
-461	NULL
-~480	NULL
ATTCTCAGGA	NULL
TCCTTCAGTT	NULL
CGCCGCATCC	NULL
TTOTCCATTA	NULL
TTTGAATATT	NULL
GGAGGCTGce	NULL
TGACCAGAAT	NULL
CTTGTCAGGA	NULL
-401	NULL
~400	NULL
CTTRGCTCCT	NULL
TCATCCCAGG	NULL
TGGTCCCGGC	NULL
TGACTCCTGA	NULL
GGACGTTACA	NULL
GCCCTGAGGG	NULL
GAGGACTCAG	NULL
CTTATGAACT	NULL
-321	NULL
xB	NULL
CArG	NULL
site	NULL
motif	NULL
-320	NULL
GCTGceTcac	NULL
AccAcTGCcA	NULL
AGAAGTGCTT	NULL
GCTeacccta	NULL
CCG	NULL
PARI	NULL
-240	NULL
TAGCTGAAGA	NULL
AAGGATTCAT	NULL
AMATGAAGTT	NULL
CAATCCTTCT	NULL
CATCAACCCC	NULL
AGCCCACACC	NULL
TCCAGCAATT	NULL
GAACTIGAMA	NULL
-161	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
Elf-1	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
site	NULL
site	NULL
site	NULL
site	NULL
-160	NULL
AAAAAAACCT	NULL
GGTTTGAAAA	NULL
A	NULL
&	NULL
A	NULL
ACtata	NULL
ATCasasaa	NULL
soaonamanon	NULL
ans	NULL
a	NULL
A	NULL
~*2	NULL
PARI	NULL
-80	NULL
AG	NULL
GCAGTTTCCT	NULL
GGCTGAACAC	NULL
GCCAGCCCAA	NULL
TACTTAAAGA	NULL
GAGCAACTCC	NULL
TGACTCCGAT	NULL
-1	NULL
AGAGACTGGA	NULL
TGGACCCACA	NULL
AGGGTGACAG	NULL
CCCAGGCGGA	NULL
CCGATCTTCC	NULL
CATCCCACAT	NULL
CCTCCGGCGC	NULL
GATGCCAAAA	NULL
80	NULL
81	NULL
AGAGGCTGAC	NULL
GGCAACTGGG	NULL
CCTTCTGCA	NULL
109	NULL
e	NULL
[	NULL
J	NULL
Uninduced	NULL
B	NULL
IL-2	NULL
induced	NULL
3	NULL
-37|80	NULL
GAS-c/EBS	NULL
GAS-n~/GATA	NULL
EBS	NULL
-37IOS	NULL
Human	NULL
..	NULL

Relative	NULL
CAT	NULL
activity	NULL
3	NULL
8	NULL
&	NULL
Y	NULL
8	NULL
-a	NULL
o	NULL
o	NULL
Murine	NULL
G2GCAGTTTCLTCTGAGAACTACCAGACATIT	NULL
TCTGATAARACAGT-CAGCAAG	NULL
CTGATAT-CTGAGACTCAGCTT	NULL
I	NULL
1375	NULL
GAS	NULL
GAS-GATA	NULL
EBS	NULL
-1299	NULL
pBLCAT2	NULL
PRRIII	NULL
GAS-c	NULL
GASn	NULL
-	NULL
EBS	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
-4103	NULL
to	NULL
+109	NULL
sequence	NULL
from	NULL
the	NULL
IL-2Ra	NULL
gene	NULL
(	NULL
GenBank	NULL
accession	NULL
number	NULL
US7613	NULL
)	NULL
.	NULL

Boxed	NULL
are	NULL
PRRI	NULL
(	NULL
-276	NULL
to	NULL
-244	NULL
,	NULL
containing	NULL
an	NULL
NF-xB	NULL
site	NULL
and	NULL
a	NULL
CArG	NULL
motif	NULL
capable	NULL
of	NULL
binding	NULL
SRF	NULL
)	NULL
,	NULL
PRRII	NULL
[	NULL
-137	NULL
to	NULL
-64.	NULL
containing	NULL
Elf-1	NULL
and	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
]	NULL
and	NULL
PRRIII	NULL
(	NULL
-3780	NULL
to	NULL
-3703	NULL
,	NULL
containing	NULL
a	NULL
consensus	NULL
GAS	NULL
motif	NULL
,	NULL
a	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
and	NULL
an	NULL
Ets	NULL
binding	NULL
site	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
PRRIII	NULL
highlighting	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
with	NULL
the	NULL
overlapping	NULL
EBS	NULL
(	NULL
GAS-c/EBS	NULL
)	NULL
,	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
with	NULL
its	NULL
overlapping	NULL
GATA	NULL
motif	NULL
(	NULL
GAS-n/GATA	NULL
)	NULL
and	NULL
the	NULL
separated	NULL
EBS	NULL
.	NULL

(	NULL
C	NULL
)	NULL
IL-2-induced	NULL
activities	NULL
in	NULL
transfected	NULL
YT	NULL
cells	NULL
of	NULL
the	NULL
full-length	NULL
PRRIII	NULL
,	NULL
GAS-c	NULL
(	NULL
-3780	NULL
to	NULL
-3756	NULL
)	NULL
,	NULL
GAS-n	NULL
(	NULL
-3757	NULL
to	NULL
-3737	NULL
)	NULL
and	NULL
EBS	NULL
(	NULL
-3734	NULL
to	NULL
-3703	NULL
)	NULL
oligonucleotides	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
TK	NULL
promoter	NULL
in	NULL
pBLCAT2	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
pBLCAT2	NULL
without	NULL
treatment	NULL
was	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1	NULL
,	NULL
and	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
other	NULL
constructs	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
increase	NULL
over	NULL
this	NULL
activity	NULL
.	NULL

The	NULL
means	NULL
+	NULL
SEM	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
expressed	NULL
relative	NULL
to	NULL
this	NULL
activity	NULL
.	NULL

5629	NULL
$	NULL
.John	NULL
,	NULL
C.M.Robbins	NULL
and	NULL
W.J.Leonard	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Characterization	NULL
of	NULL
PRRIII	NULL
binding	NULL
proteins	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSAs	NULL
using	NULL
full-length	NULL
PRRIII	NULL
,	NULL
-3780	NULL
to	NULL
-3703	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
IL-2-induced	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
preactivated	NULL
PBL	NULL
.	NULL

Four	NULL
major	NULL
DNA	NULL
binding	NULL
complexes	NULL
,	NULL
C1-C4	NULL
,	NULL
that	NULL
are	NULL
reproducibly	NULL
seen	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Methylation	NULL
interference	NULL
analysis	NULL
of	NULL
C1	NULL
,	NULL
C2	NULL
and	NULL
C4	NULL
.	NULL

Shown	NULL
are	NULL
piperidine-mediated	NULL
cleavage	NULL
of	NULL
free	NULL
probe	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
11	NULL
,	NULL
13	NULL
and	NULL
15	NULL
)	NULL
or	NULL
of	NULL
PRRIII	NULL
bound	NULL
to	NULL
protein	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
12	NULL
,	NULL
14	NULL
and	NULL
16	NULL
)	NULL
.	NULL

TOP	NULL
and	NULL
BOT	NULL
refer	NULL
to	NULL
the	NULL
sense	NULL
(	NULL
top	NULL
)	NULL
and	NULL
antisense	NULL
(	NULL
bottom	NULL
)	NULL
strands	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
apparent	NULL
protections	NULL
of	NULL
the	NULL
bands	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
lanes	NULL
2	NULL
,	NULL
6	NULL
,	NULL
10	NULL
and	NULL
14	NULL
are	NULL
artefactual	NULL
since	NULL
those	NULL
nucleotides	NULL
correspond	NULL
to	NULL
artificial	NULL
overhangs	NULL
rather	NULL
than	NULL
PRRIII	NULL
sequences	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Summary	NULL
of	NULL
methylation	NULL
interference	NULL
analysis	NULL
.	NULL

Filled	NULL
circles	NULL
represent	NULL
strong	NULL
protection	NULL
and	NULL
open	NULL
circles	NULL
indicate	NULL
weak	NULL
protection	NULL
.	NULL

investigated	NULL
whether	NULL
Elf-1	NULL
could	NULL
also	NULL
bind	NULL
to	NULL
the	NULL
putative	NULL
EBSs	NULL
in	NULL
PRRIII	NULL
.	NULL

/n	NULL
vitro	NULL
translated	NULL
Elf-1	NULL
protein	NULL
(	NULL
Figure	NULL
4B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
but	NULL
not	NULL
control	NULL
lysate	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
generated	NULL
two	NULL
complexes	NULL
that	NULL
co-migrated	NULL
with	NULL
the	NULL
C2	NULL
and	NULL
C3	NULL
complexes	NULL
formed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBL	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

C3	NULL
is	NULL
5630	NULL
therefore	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
degradation	NULL
product	NULL
of	NULL
Elf-1	NULL
,	NULL
the	NULL
existence	NULL
of	NULL
which	NULL
was	NULL
previously	NULL
suggested	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Elf-1	NULL
binds	NULL
to	NULL
both	NULL
the	NULL
-3734	NULL
to	NULL
-3703	NULL
and	NULL
-3780	NULL
to	NULL
-3756	NULL
oligonucleotides	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
,	NULL
each	NULL
of	NULL
which	NULL
contains	NULL
an	NULL
EBS	NULL
,	NULL
but	NULL
not	NULL
to	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
GAS-c/RBS	NULL
PRAI	NULL
WT	NULL
.	NULL

GAS-n/GATA	NULL
Eas	NULL
macommacamirroreatAaaanrroaccan	NULL
Toxaatancactcaccrrg	NULL
M1.0	NULL
M11	NULL
M1.2	NULL
MBL	NULL
|	NULL
i	NULL
Co	NULL
fuged	NULL
igen	NULL
tE	NULL
M2.2	NULL
Probe	NULL
_WT_	NULL
M1.0	NULL
M1.1	NULL
M12	NULL
M2.1	NULL
M22	NULL
_M3_	NULL
_MS5_	NULL
M6_	NULL
L-2	NULL
+	NULL
-	NULL
+	NULL
£0	NULL
-	NULL
#	NULL
-	NULL
#	NULL
~	NULL
#	NULL
-	NULL
+	NULL
+	NULL
z	NULL
w	NULL
cs	NULL
#	NULL
1	NULL
«	NULL
sU8E	NULL
:	NULL
2	NULL
3	NULL
4	NULL
5	NULL
°	NULL
6	NULL
7	NULL
8	NULL
9°	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
18	NULL
16	NULL
171	NULL
c	NULL
C	NULL
__	NULL
Binding	NULL
Activity	NULL
C1	NULL
C2	NULL
C3	NULL
C4	NULL
WT	NULL
-	NULL
[	NULL
GASc	NULL
(	NULL
EBS	NULL
)	NULL
}	NULL
-	NULL
{	NULL
GASn	NULL
(	NULL
GATAJ-	NULL
{	NULL
[	NULL
EBS	NULL
|-	NULL
++	NULL
++	NULL
++	NULL
++	NULL
_i	NULL
ESS	NULL
/j	NULL
Lane	NULL
!	NULL

Wan	NULL
Ad	NULL
M1.0	NULL
@	NULL
Cess	NULL
)	NULL
(	NULL
Gasn	NULL
GAAI-CEBS	NULL
)	NULL
-	NULL
44+	NULL
++	NULL
++	NULL
M11	NULL
Gass	NULL
Ga-	NULL
Es	NULL
}	NULL
-	NULL
+	NULL
+	NULL
_	NULL
-/+	NULL
M1.2	NULL
-	NULL
C	NULL
{	NULL
Gasn	NULL
Gat	NULL
}	NULL
|-	NULL
-	NULL
+	NULL
$	NULL
000	NULL
M2.1	NULL
~1GASc	NULL
(	NULL
EBS	NULL
)	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

EMSAs	NULL
using	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
PRRIII	NULL
oligonucleotides	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequence	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
WT	NULL
)	NULL
PRRIII	NULL
oligonucleotide	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
GAS-c/EBS	NULL
,	NULL
GAS-n/GATA	NULL
and	NULL
EBS	NULL
are	NULL
indicated	NULL
.	NULL

For	NULL
the	NULL
mutant	NULL
oligonucleotides	NULL
,	NULL
only	NULL
the	NULL
mutations	NULL
are	NULL
shown	NULL
;	NULL
hyphens	NULL
indicate	NULL
sequence	NULL
identity	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSAs	NULL
using	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
PRRIII	NULL
oligonucleotides	NULL
:	NULL
wild	NULL
type	NULL
PRRIII	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
mutant	NULL
M1.0	NULL
,	NULL
mutation	NULL
of	NULL
consensus	NULL
GAS	NULL
motif	NULL
leaving	NULL
intact	NULL
the	NULL
EBS	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
;	NULL
mutant	NULL
M1.1	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
overlapping	NULL
EBS	NULL
in	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
;	NULL
mutant	NULL
M1.2	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
overlapping	NULL
EBS	NULL
and	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
;	NULL
mutant	NULL
M2.1	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
non-consensus	NULL
GAS	NULL
and	NULL
GATA	NULL
motifs	NULL
,	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
;	NULL
mutant	NULL
M2.2	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
GATA	NULL
motif	NULL
,	NULL
which	NULL
overlaps	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
;	NULL
mutant	NULL
M3	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
downstream	NULL
EBS	NULL
between	NULL
-3705	NULL
and	NULL
-3702	NULL
(	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
;	NULL
mutant	NULL
MS	NULL
,	NULL
mutation	NULL
of	NULL
both	NULL
GAS	NULL
motifs	NULL
(	NULL
lanes	NULL
15	NULL
and	NULL
16	NULL
)	NULL
;	NULL
mutant	NULL
M6	NULL
.	NULL

mutation	NULL
of	NULL
all	NULL
protein	NULL
binding	NULL
sites	NULL
(	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
.	NULL

In	NULL
some	NULL
lanes	NULL
,	NULL
including	NULL
3	NULL
,	NULL
4	NULL
.	NULL

9	NULL
,	NULL
10	NULL
.	NULL

13	NULL
,	NULL
14	NULL
,	NULL
17	NULL
and	NULL
18	NULL
,	NULL
new	NULL
binding	NULL
activities	NULL
are	NULL
seen	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
binding	NULL
activities	NULL
are	NULL
also	NULL
seen	NULL
as	NULL
faint	NULL
bands	NULL
at	NULL
the	NULL
same	NULL
positions	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
PRRIH	NULL
probe	NULL
.	NULL

Although	NULL
the	NULL
origin	NULL
and	NULL
significance	NULL
of	NULL
the	NULL
new	NULL
bands	NULL
are	NULL
unclear	NULL
,	NULL
they	NULL
may	NULL
represent	NULL
the	NULL
enhanced	NULL
abilities	NULL
of	NULL
other	NULL
factors	NULL
that	NULL
can	NULL
potentially	NULL
bind	NULL
to	NULL
PRRIII	NULL
when	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
major	NULL
complexes	NULL
,	NULL
C1-C4	NULL
are	NULL
inhibited	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
mutations	NULL
.	NULL

Alternatively	NULL
,	NULL
they	NULL
could	NULL
represent	NULL
new	NULL
binding	NULL
sites	NULL
created	NULL
by	NULL
the	NULL
mutations	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Summary	NULL
of	NULL
binding	NULL
activities	NULL
.	NULL

IL-2	NULL
response	NULL
element	NULL
in	NULL
human	NULL
promoter	NULL
1	NULL
444	NULL
TY	NULL
€€	NULL
Ps	NULL
4	NULL
p-TC	NULL
pro	NULL
apy	NULL
t€	NULL
rg	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Identification	NULL
of	NULL
proteins	NULL
contained	NULL
in	NULL
complexes	NULL
C1	NULL
.	NULL

C2	NULL
(	NULL
C3	NULL
)	NULL
and	NULL
C4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
C4	NULL
contains	NULL
Stat5	NULL
.	NULL

Stat5A	NULL
and	NULL
Stat5B	NULL
specific	NULL
antisera	NULL
supershift	NULL
C4	NULL
but	NULL
not	NULL
C1	NULL
.	NULL

C2	NULL
or	NULL
C3	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
versus	NULL
2	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
in	NULL
vitro	NULL
translated	NULL
Elf-1	NULL
binds	NULL
to	NULL
PRRIII	NULL
.	NULL

Lane	NULL
1	NULL
shows	NULL
binding	NULL
of	NULL
uninduced	NULL
preactivated	NULL
PBL	NULL
nuclear	NULL
extract	NULL
to	NULL
PRRIII	NULL
.	NULL

Binding	NULL
of	NULL
unprogrammed	NULL
lysates	NULL
(	NULL
lanes	NULL
3	NULL
.	NULL

4	NULL
.	NULL

6	NULL
and	NULL
8	NULL
)	NULL
or	NULL
Elf-1	NULL
programmed	NULL
lysates	NULL
(	NULL
lane	NULL
2	NULL
,	NULL
5	NULL
,	NULL
7	NULL
and	NULL
9	NULL
)	NULL
to	NULL
PRRIII	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

-3734	NULL
to	NULL
-3703	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

-3780	NULL
to	NULL
-3756	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
and	NULL
-3757	NULL
to	NULL
-3737	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
oligonucleotides	NULL
.	NULL

(	NULL
C	NULL
)	NULL
C2	NULL
and	NULL
C4	NULL
contain	NULL
Elf-1	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
show	NULL
binding	NULL
of	NULL
proteins	NULL
in	NULL
preactivated	NULL
PBL	NULL
nuclear	NULL
extracts	NULL
to	NULL
PRRIII	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
antibody	NULL
added	NULL
.	NULL

An	NULL
anti-Elf-1	NULL
antibody	NULL
supershifts	NULL
C2	NULL
and	NULL
C3	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
decreases	NULL
the	NULL
intensity	NULL
of	NULL
C4	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Complex	NULL
C1	NULL
seen	NULL
with	NULL
uninduced	NULL
preactivated	NULL
PBL	NULL
extracts	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
preincubation	NULL
with	NULL
an	NULL
anti-Elf-1	NULL
antibody	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
GATA	NULL
proteins	NULL
are	NULL
present	NULL
in	NULL
C4	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
preactivated	NULL
PBL	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
1	NULL
ul	NULL
of	NULL
anti-GATA-1	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
or	NULL
GATA-3	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
specific	NULL
antibodies	NULL
.	NULL

the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
(	NULL
-3757	NULL
to	NULL
-3737	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
Elf-1	NULL
in	NULL
C2	NULL
and	NULL
C3	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
Elf-1	NULL
to	NULL
supershift	NULL
C2	NULL
and	NULL
C3	NULL
(	NULL
Figure	NULL
4C	NULL
,	NULL
lane	NULL
3	NULL
versus	NULL
1	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
supershifted	NULL
complexes	NULL
in	NULL
lane	NULL
3	NULL
superimposed	NULL
on	NULL
complex	NULL
C1	NULL
,	NULL
it	NULL
was	NULL
unclear	NULL
if	NULL
C1	NULL
was	NULL
also	NULL
affected	NULL
by	NULL
the	NULL
Elf-1	NULL
antibody	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
same	NULL
antibody	NULL
was	NULL
preincubated	NULL
with	NULL
uninduced	NULL
nuclear	NULL
extracts	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
probe	NULL
,	NULL
it	NULL
primarily	NULL
diminished	NULL
Elf-1	NULL
complexes	NULL
(	NULL
C2	NULL
and	NULL
C3	NULL
)	NULL
,	NULL
showing	NULL
that	NULL
complex	NULL
C1	NULL
was	NULL
not	NULL
affected	NULL
and	NULL
therefore	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
contain	NULL
Elf-1	NULL
(	NULL
lane	NULL
6	NULL
versus	NULL
5	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
contained	NULL
in	NULL
Cl	NULL
are	NULL
not	NULL
yet	NULL
known	NULL
.	NULL

The	NULL
anti-Elf-1	NULL
antibody	NULL
also	NULL
modestly	NULL
decreased	NULL
the	NULL
intensity	NULL
of	NULL
C4	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
2	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
possibility	NULL
that	NULL
C4	NULL
might	NULL
contain	NULL
Elf-1	NULL
as	NULL
well	NULL
as	NULL
Stat5	NULL
.	NULL

As	NULL
indicated	NULL
in	NULL
Figure	NULL
1B	NULL
,	NULL
a	NULL
putative	NULL
GATA	NULL
binding	NULL
5631	NULL
S.John	NULL
,	NULL
C.M.Robbins	NULL
and	NULL
W.J.Leonard	NULL
motif	NULL
overlaps	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
.	NULL

GATA-3	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
lineage	NULL
restricted	NULL
factor	NULL
that	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
genes	NULL
(	NULL
Ho	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
GATA-3	NULL
could	NULL
bind	NULL
to	NULL
PRRIII	NULL
,	NULL
we	NULL
performed	NULL
antibody	NULL
supershift	NULL
analysis	NULL
with	NULL
a	NULL
GATA-3	NULL
antibody	NULL
.	NULL

A	NULL
GATA-1	NULL
antibody	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
,	NULL
since	NULL
GATA-1	NULL
proteins	NULL
have	NULL
only	NULL
been	NULL
detected	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
erythroid	NULL
lineage	NULL
(	NULL
reviewed	NULL
in	NULL
Weiss	NULL
and	NULL
Orkin	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
the	NULL
antibody	NULL
specific	NULL
for	NULL
GATA-1	NULL
generated	NULL
a	NULL
supershifted	NULL
complex	NULL
with	NULL
IL-2-induced	NULL
extracts	NULL
(	NULL
Figure	NULL
4D	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
but	NULL
not	NULL
uninduced	NULL
extracts	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
it	NULL
recognizing	NULL
a	NULL
component	NULL
of	NULL
complex	NULL
C4	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
two	NULL
different	NULL
antibodies	NULL
to	NULL
GATA-3	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
upon	NULL
IL-2	NULL
stimulation	NULL
,	NULL
GATA-1	NULL
or	NULL
a	NULL
closely	NULL
related	NULL
protein	NULL
binds	NULL
to	NULL
PRRIII	NULL
as	NULL
part	NULL
of	NULL
a	NULL
complex	NULL
that	NULL
also	NULL
contains	NULL
Stat5	NULL
and	NULL
Elf-1	NULL
proteins	NULL
.	NULL

HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binds	NULL
to	NULL
PRRIII	NULL
In	NULL
the	NULL
EMSAs	NULL
performed	NULL
with	NULL
the	NULL
PRRIII	NULL
oligonucleotide	NULL
we	NULL
used	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
to	NULL
eliminate	NULL
non-specific	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
.	NULL

We	NULL
sometimes	NULL
observed	NULL
a	NULL
faint	NULL
complex	NULL
with	NULL
rapid	NULL
mobility	NULL
,	NULL
typical	NULL
of	NULL
that	NULL
resulting	NULL
from	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
high	NULL
mobility	NULL
group	NULL
proteins	NULL
,	NULL
HMG-I	NULL
and	NULL
HMG-Y	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

When	NULL
EMSAs	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
[	NULL
or	NULL
poly	NULL
(	NULL
dG-dC	NULL
)	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
]	NULL
as	NULL
the	NULL
non-specific	NULL
com-petitor	NULL
,	NULL
a	NULL
complex	NULL
was	NULL
consistently	NULL
observed	NULL
(	NULL
Figure	NULL
5B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
that	NULL
co-migrated	NULL
with	NULL
the	NULL
complex	NULL
formed	NULL
with	NULL
purified	NULL
recombinant	NULL
HMG-I	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

EMSAs	NULL
performed	NULL
with	NULL
a	NULL
series	NULL
of	NULL
mutant	NULL
PRRIII	NULL
oligonucleotides	NULL
(	NULL
see	NULL
Figure	NULL
5A	NULL
for	NULL
sequences	NULL
)	NULL
revealed	NULL
that	NULL
this	NULL
binding	NULL
activity	NULL
was	NULL
decreased	NULL
with	NULL
oligonucleotides	NULL
which	NULL
contain	NULL
mutations	NULL
in	NULL
the	NULL
Elf-1	NULL
binding	NULL
site	NULL
located	NULL
between	NULL
-3725	NULL
and	NULL
-3724	NULL
(	NULL
M3	NULL
and	NULL
M6	NULL
,	NULL
Figure	NULL
5B	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
12	NULL
versus	NULL
3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
residual	NULL
HMG-I	NULL
binding	NULL
seen	NULL
with	NULL
mutant	NULL
M3	NULL
was	NULL
abrogated	NULL
when	NULL
the	NULL
A-T	NULL
rich	NULL
sequence	NULL
within	NULL
the	NULL
GATA	NULL
motif	NULL
was	NULL
simultaneously	NULL
mutated	NULL
(	NULL
mutant	NULL
M8	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
,	NULL
while	NULL
mutation	NULL
of	NULL
the	NULL
GATA	NULL
motif	NULL
alone	NULL
had	NULL
a	NULL
minimal	NULL
effect	NULL
(	NULL
mutant	NULL
M7	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binds	NULL
to	NULL
two	NULL
different	NULL
sequences	NULL
in	NULL
PRRIII	NULL
,	NULL
overlapping	NULL
the	NULL
Elf-1	NULL
binding	NULL
site	NULL
and	NULL
the	NULL
GATA	NULL
motif	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
major	NULL
HMG-I	NULL
binding	NULL
site	NULL
overlaps	NULL
the	NULL
EIf-1	NULL
motif	NULL
since	NULL
mutation	NULL
of	NULL
this	NULL
site	NULL
caused	NULL
the	NULL
greatest	NULL
decrease	NULL
in	NULL
HMG-I	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
coordinated	NULL
activity	NULL
of	NULL
each	NULL
of	NULL
the	NULL
binding	NULL
sites	NULL
in	NULL
PRRIII	NULL
is	NULL
required	NULL
for	NULL
the	NULL
IL-2	NULL
inducibility	NULL
of	NULL
IL-2Ra	NULL
promoter	NULL
The	NULL
above	NULL
studies	NULL
indicate	NULL
that	NULL
the	NULL
human	NULL
IL-2R	NULL
&	NULL
IL-2	NULL
response	NULL
element	NULL
is	NULL
a	NULL
complex	NULL
structure	NULL
containing	NULL
two	NULL
GAS	NULL
motifs	NULL
,	NULL
a	NULL
GATA	NULL
motif	NULL
,	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
and	NULL
two	NULL
EBSs	NULL
.	NULL

To	NULL
clarify	NULL
the	NULL
functional	NULL
significance	NULL
and	NULL
relative	NULL
contributions	NULL
of	NULL
each	NULL
of	NULL
these	NULL
sites	NULL
,	NULL
we	NULL
performed	NULL
site	NULL
directed	NULL
mutagenesis	NULL
analysis	NULL
of	NULL
the	NULL
-4103	NULL
to	NULL
+109	NULL
IL-2R	NULL
&	NULL
-CAT	NULL
construct	NULL
(	NULL
mutations	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
3A	NULL
)	NULL
and	NULL
assayed	NULL
for	NULL
IL-2	NULL
responsiveness	NULL
of	NULL
mutant	NULL
constructs	NULL
in	NULL
YT	NULL
cells	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
construct	NULL
consistently	NULL
showed	NULL
a	NULL
3-	NULL
to	NULL
4-fold	NULL
IL-2	NULL
inducibility	NULL
in	NULL
YT	NULL
cells	NULL
(	NULL
Figure	NULL
6	NULL
,	NULL
WT	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
overlapping	NULL
EBS	NULL
in	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
(	NULL
mutant	NULL
M1.1	NULL
)	NULL
,	NULL
which	NULL
abrogates	NULL
C1	NULL
binding	NULL
activity	NULL
but	NULL
importantly	NULL
still	NULL
retains	NULL
weak	NULL
C4	NULL
binding	NULL
activity	NULL
,	NULL
significantly	NULL
increased	NULL
basal	NULL
activity	NULL
,	NULL
5632	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binds	NULL
to	NULL
PRRIII	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nucleotide	NULL
sequences	NULL
of	NULL
PRRIII	NULL
oligonucleotides	NULL
used	NULL
for	NULL
EMSAs	NULL
in	NULL
(	NULL
B	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSAs	NULL
showing	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
preactivated	NULL
PBL	NULL
not	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
recombinant	NULL
purified	NULL
HMG-I	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
PRRIII	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
as	NULL
the	NULL
non-specific	NULL
competitor	NULL
.	NULL

Binding	NULL
of	NULL
recombinant	NULL
purified	NULL
HMG-I	NULL
to	NULL
WT	NULL
or	NULL
mutant	NULL
PRRIII	NULL
oligonucleotides	NULL
;	NULL
lane	NULL
3	NULL
shows	NULL
binding	NULL
to	NULL
WT	NULL
,	NULL
lanes	NULL
4-14	NULL
are	NULL
binding	NULL
to	NULL
mutants	NULL
M1.0	NULL
,	NULL
M1L.1	NULL
,	NULL
M1.2	NULL
,	NULL
M2	NULL
,	NULL
M2.1	NULL
,	NULL
M3	NULL
,	NULL
M4	NULL
,	NULL
M5	NULL
,	NULL
M6	NULL
,	NULL
M7	NULL
and	NULL
M8	NULL
.	NULL

thus	NULL
decreasing	NULL
the	NULL
IL-2	NULL
inducibility	NULL
of	NULL
this	NULL
construct	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
which	NULL
bind	NULL
to	NULL
this	NULL
site	NULL
may	NULL
negatively	NULL
regulate	NULL
the	NULL
IL-2Ro	NULL
promoter	NULL
.	NULL

Interestingly	NULL
,	NULL
mutation	NULL
of	NULL
this	NULL
same	NULL
consensus	NULL
GAS	NULL
motif	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
affected	NULL
both	NULL
the	NULL
STAT	NULL
and	NULL
Ets	NULL
binding	NULL
sites	NULL
(	NULL
mutant	NULL
MI1.2	NULL
)	NULL
,	NULL
which	NULL
shows	NULL
no	NULL
detectable	NULL
C1	NULL
or	NULL
C4	NULL
binding	NULL
activity	NULL
,	NULL
restored	NULL
basal	NULL
activity	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
construct	NULL
;	NULL
in	NULL
addition	NULL
,	NULL
it	NULL
exhibited	NULL
a	NULL
modest	NULL
but	NULL
reproducible	NULL
decrease	NULL
in	NULL
IL-2-induced	NULL
promoter	NULL
activity	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
the	NULL
WT	NULL
construct	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
IL-2-induced	NULL
transcriptional	NULL
activity	NULL
observed	NULL
with	NULL
mutants	NULL
M1.1	NULL
and	NULL
M1.2	NULL
might	NULL
result	NULL
from	NULL
the	NULL
ability	NULL
of	NULL
M1.1	NULL
,	NULL
but	NULL
not	NULL
M1.2	NULL
,	NULL
to	NULL
form	NULL
the	NULL
inducible	NULL
complex	NULL
C4	NULL
.	NULL

Remarkably	NULL
,	NULL
mutant	NULL
M2.1	NULL
,	NULL
which	NULL
affected	NULL
only	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
and	NULL
overlapping	NULL
GATA	NULL
motif	NULL
,	NULL
displayed	NULL
a	NULL
profound	NULL
reduction	NULL
in	NULL
both	NULL
basal	NULL
and	NULL
IL-2	NULL
inducible	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
motifs	NULL
are	NULL
essential	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2Ra	NULL
&	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
mutant	NULL
M2.2	NULL
,	NULL
which	NULL
affects	NULL
the	NULL
GATA	NULL
motif	NULL
,	NULL
although	NULL
there	NULL
was	NULL
a	NULL
decrease	NULL
in	NULL
both	NULL
basal	NULL
and	NULL
IL-2-induced	NULL
levels	NULL
of	NULL
activity	NULL
;	NULL
some	NULL
IL-2-induced	NULL
activity	NULL
was	NULL
still	NULL
seen	NULL
,	NULL
indicating	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
the	NULL
non-consensus	NULL
GAS	NULL
motif	NULL
.	NULL

Interestingly	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
downstream	NULL
EBS	NULL
(	NULL
mutant	NULL
M3	NULL
)	NULL
,	NULL
which	NULL
affects	NULL
Elf-1	NULL
and	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
,	NULL
showed	NULL
a	NULL
greater	NULL
decrease	NULL
in	NULL
IL-2	NULL
inducibility	NULL
than	NULL
mutants	NULL
MI1.1	NULL
,	NULL
M1.2	NULL
and	NULL
M2.2	NULL
,	NULL
all	NULL
of	NULL
which	NULL
displayed	NULL
greatly	NULL
diminished	NULL
or	NULL
a	NULL
total	NULL
loss	NULL
of	NULL
STAT	NULL
protein	NULL
binding	NULL
activity	NULL
.	NULL

pBLCAT3	NULL
[	NULL
-~	NULL
C	NULL
ML~	NULL
@	NULL
»	NULL
DD	NULL
IL-2	NULL
response	NULL
element	NULL
in	NULL
human	NULL
IL-2Ra	NULL
promoter	NULL
Relative	NULL
CAT	NULL
Activity	NULL
0	NULL
4.5	NULL
9	NULL
13	NULL
.	NULL

|	NULL
ENA	NULL
*i	NULL
C_	NULL
ENHAT_	NULL
}	NULL
-	NULL
yani	NULL
--	NULL
on	NULL
_	NULL
:	NULL
co	NULL
Ef	NULL
|	NULL
Cam	NULL
}	NULL
|	NULL
M1	NULL
.	NULL

2-6	NULL
:	NULL
p	NULL
)	NULL
)	NULL
een	NULL
ean	NULL
M2.1	NULL
{	NULL
VéﬁfsfzéwlyéBévéﬁxcn—fé	NULL
Ka-M2.2	NULL
-	NULL
[	NULL
GAS	NULL
'	NULL
c	NULL
(	NULL
EBs	NULL
)	NULL
]	NULL
-	NULL
(	NULL
GASn	NULL
CKA	NULL
--	NULL
[	NULL
EIM	NULL
%	NULL
B	NULL
M3	NULL
-	NULL
[	NULL
GaAS-c	NULL
(	NULL
EBS	NULL
)	NULL
]	NULL
-	NULL
[	NULL
GASn	NULL
33:1	NULL
Vi	NULL
-4103/+109	NULL
IL-2R	NULL
«	NULL
CAT	NULL
-	NULL
§	NULL
)	NULL
Uninduced	NULL
M6	NULL
-	NULL
ﬁg	NULL
E	NULL
ﬁfgﬂfﬁgﬂff	NULL
i	NULL
|Lrj12nandCuecﬂec	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

All	NULL
components	NULL
of	NULL
PRRIII	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
IL-2	NULL
responsiveness	NULL
.	NULL

Mutations	NULL
in	NULL
PRR	NULL
III	NULL
were	NULL
incorporated	NULL
into	NULL
4103	NULL
to	NULL
+109	NULL
IL-2R	NULL
&	NULL
-CAT	NULL
reporter	NULL
constructs	NULL
and	NULL
transfected	NULL
into	NULL
YT	NULL
cells	NULL
.	NULL

followed	NULL
by	NULL
no	NULL
stimulation	NULL
or	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

Mutations	NULL
are	NULL
designated	NULL
as	NULL
in	NULL
Figure	NULL
3A	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
pBLCAT3	NULL
in	NULL
cells	NULL
not	NULL
stimulated	NULL
with	NULL
IL-2	NULL
was	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1.	NULL
and	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
other	NULL
constructs	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
increase	NULL
over	NULL
this	NULL
activity	NULL
.	NULL

The	NULL
means	NULL
+	NULL
SEM	NULL
for	NULL
seven	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
binding	NULL
of	NULL
Elf-1	NULL
and	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
are	NULL
essential	NULL
for	NULL
IL-2-induced	NULL
activation	NULL
of	NULL
PRRIII	NULL
.	NULL

Finally	NULL
,	NULL
simultaneous	NULL
mutation	NULL
of	NULL
all	NULL
the	NULL
components	NULL
of	NULL
PRRIII	NULL
(	NULL
mutant	NULL
M6	NULL
)	NULL
,	NULL
abrogated	NULL
IL-2R	NULL
&	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
functional	NULL
cooperativity	NULL
between	NULL
Stat5	NULL
,	NULL
GATA	NULL
proteins	NULL
,	NULL
Elf-1	NULL
and	NULL
HMG-I	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
IL-2-induced	NULL
IL-2Ra	NULL
&	NULL
promoter	NULL
activity	NULL
.	NULL

Discussion	NULL
IL-2Ra	NULL
transcription	NULL
is	NULL
tightly	NULL
regulated	NULL
in	NULL
a	NULL
lineage-	NULL
and	NULL
activation-dependent	NULL
manner	NULL
.	NULL

IL-2	NULL
itself	NULL
is	NULL
an	NULL
activator	NULL
of	NULL
IL-2Ra	NULL
gene	NULL
expression	NULL
,	NULL
thereby	NULL
modulating	NULL
the	NULL
number	NULL
of	NULL
high	NULL
affinity	NULL
IL-2	NULL
receptors	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

IL-2R	NULL
«	NULL
&	NULL
is	NULL
therefore	NULL
perhaps	NULL
one	NULL
of	NULL
the	NULL
most	NULL
important	NULL
genes	NULL
activated	NULL
by	NULL
IL-2	NULL
making	NULL
it	NULL
essential	NULL
to	NULL
understand	NULL
the	NULL
molecular	NULL
basis	NULL
underlying	NULL
IL-2-induced	NULL
IL-2Ra	NULL
regulation	NULL
.	NULL

Since	NULL
IL-2	NULL
activates	NULL
the	NULL
STAT	NULL
proteins	NULL
Stat5	NULL
and	NULL
Stat3	NULL
(	NULL
Nielsen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Fujii	NULL
et	NULL
al..	NULL
,	NULL
1995	NULL
;	NULL
Gaffen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Gilmour	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Hou	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Wakao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
it	NULL
was	NULL
likely	NULL
that	NULL
STAT	NULL
proteins	NULL
would	NULL
play	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
IL-2-induced	NULL
IL-2R	NULL
«	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
study	NULL
.	NULL

we	NULL
report	NULL
a	NULL
detailed	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
response	NULL
element	NULL
,	NULL
PRRIII	NULL
,	NULL
which	NULL
is	NULL
essential	NULL
for	NULL
IL-2-induced	NULL
IL-2R	NULL
&	NULL
promoter	NULL
activity	NULL
.	NULL

Interestingly	NULL
,	NULL
PRRIII	NULL
is	NULL
a	NULL
complex	NULL
composite	NULL
unit	NULL
that	NULL
is	NULL
composed	NULL
of	NULL
binding	NULL
sites	NULL
not	NULL
only	NULL
for	NULL
the	NULL
IL-2-inducible	NULL
STAT	NULL
proteins	NULL
,	NULL
StatSA	NULL
and	NULL
Stat5B	NULL
,	NULL
but	NULL
also	NULL
for	NULL
the	NULL
lymphoid/myeloid-specific	NULL
Ets	NULL
family	NULL
protein	NULL
,	NULL
Elf-1	NULL
.	NULL

the	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
,	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
and	NULL
a	NULL
GATA-1	NULL
-like	NULL
protein	NULL
.	NULL

The	NULL
combinatorial	NULL
nature	NULL
of	NULL
PRRIII	NULL
is	NULL
reflected	NULL
in	NULL
the	NULL
finding	NULL
that	NULL
mutations	NULL
in	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
any	NULL
one	NULL
of	NULL
these	NULL
proteins	NULL
decreased	NULL
the	NULL
IL-2	NULL
inducibility	NULL
of	NULL
reporter	NULL
constructs	NULL
in	NULL
transfected	NULL
cells	NULL
.	NULL

This	NULL
feature	NULL
of	NULL
PRRIII	NULL
is	NULL
reminiscent	NULL
of	NULL
the	NULL
positive	NULL
regulatory	NULL
domains	NULL
of	NULL
the	NULL
B-IFN	NULL
promoter	NULL
where	NULL
multiple	NULL
factors	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
regulate	NULL
the	NULL
viral	NULL
inducibility	NULL
of	NULL
that	NULL
promoter	NULL
(	NULL
Thanos	NULL
and	NULL
Maniatis	NULL
,	NULL
1992	NULL
,	NULL
1995	NULL
;	NULL
Du	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
hypothesize	NULL
that	NULL
extensive	NULL
protein-protein	NULL
interactions	NULL
exist	NULL
between	NULL
the	NULL
various	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
PRRIII	NULL
and	NULL
that	NULL
IL-2	NULL
stimulation	NULL
of	NULL
the	NULL
IL-2R	NULL
&	NULL
promoter	NULL
induces	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
highly	NULL
ordered	NULL
'enhanceosome	NULL
'	NULL
structure	NULL
(	NULL
Thanos	NULL
and	NULL
Maniatis	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
its	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
TFIIB	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
,	NULL
Elf-1	NULL
may	NULL
be	NULL
required	NULL
to	NULL
relay	NULL
activation-induced	NULL
signals	NULL
to	NULL
the	NULL
basal	NULL
transcription	NULL
machinery	NULL
,	NULL
whereas	NULL
Stat5	NULL
binding	NULL
to	NULL
PRRIII	NULL
may	NULL
represent	NULL
the	NULL
nuclear	NULL
sequela	NULL
of	NULL
IL-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
Jak-STAT	NULL
pathway	NULL
.	NULL

In	NULL
our	NULL
transfection	NULL
studies	NULL
performed	NULL
with	NULL
mutant	NULL
IL-2R	NULL
&	NULL
constructs	NULL
,	NULL
we	NULL
found	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
downstream	NULL
Elf-1	NULL
binding	NULL
site	NULL
(	NULL
mutant	NULL
M3	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
in	NULL
IL-2	NULL
inducibility	NULL
even	NULL
though	NULL
StatS5	NULL
binding	NULL
activity	NULL
was	NULL
clearly	NULL
detectable	NULL
with	NULL
this	NULL
mutant	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
both	NULL
Elf-1	NULL
and	NULL
Stat5	NULL
binding	NULL
to	NULL
PRRIII	NULL
are	NULL
important	NULL
for	NULL
IL-2-mediated	NULL
IL-2Ro	NULL
induction	NULL
.	NULL

Several	NULL
elegant	NULL
studies	NULL
have	NULL
now	NULL
shown	NULL
that	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
proteins	NULL
can	NULL
promote	NULL
selective	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
and	NULL
induce	NULL
bends	NULL
in	NULL
DNA	NULL
thereby	NULL
facilitating	NULL
enhanceosome	NULL
-	NULL
formation	NULL
-	NULL
and	NULL
-	NULL
permitting	NULL
-	NULL
cross-talk	NULL
between	NULL
spatially	NULL
separated	NULL
transcription	NULL
factors	NULL
(	NULL
Thanos	NULL
and	NULL
Maniatis	NULL
,	NULL
1992	NULL
,	NULL
1995	NULL
;	NULL
Du	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Falvo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
previously	NULL
that	NULL
Elf-1	NULL
and	NULL
HMG-I	NULL
can	NULL
synergistically	NULL
activate	NULL
PRRII	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
Elf-1	NULL
site	NULL
in	NULL
PRRIII	NULL
is	NULL
also	NULL
juxtaposed	NULL
to	NULL
HMG-I	NULL
binding	NULL
sites	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
proteins	NULL
may	NULL
also	NULL
functionally	NULL
interact	NULL
to	NULL
regulate	NULL
the	NULL
activity	NULL
of	NULL
PRRIIL	NULL
In	NULL
addition	NULL
,	NULL
we	NULL
also	NULL
detected	NULL
a	NULL
second	NULL
lower	NULL
affinity	NULL
binding	NULL
site	NULL
for	NULL
HMG-I	NULL
,	NULL
which	NULL
overlaps	NULL
the	NULL
GATA	NULL
motif	NULL
,	NULL
a	NULL
situation	NULL
that	NULL
is	NULL
analogous	NULL
to	NULL
that	NULL
found	NULL
in	NULL
the	NULL
y-globin	NULL
promoter	NULL
,	NULL
where	NULL
HMG-I	NULL
binding	NULL
to	NULL
GATA	NULL
motifs	NULL
may	NULL
function	NULL
to	NULL
form	NULL
transcriptionally	NULL
active	NULL
multiprotein	NULL
complexes	NULL
(	NULL
Magis	NULL
and	NULL
Martin	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
similar	NULL
to	NULL
its	NULL
role	NULL
in	NULL
regulating	NULL
PRRII	NULL
activity	NULL
,	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
may	NULL
also	NULL
function	NULL
to	NULL
modulate	NULL
the	NULL
architecture	NULL
of	NULL
PRRIII	NULL
,	NULL
thereby	NULL
facilitating	NULL
functional	NULL
interactions	NULL
between	NULL
key	NULL
regulatory	NULL
proteins	NULL
such	NULL
as	NULL
Elf-1	NULL
,	NULL
Stat5	NULL
and	NULL
GATA	NULL
proteins	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
IL-2-induced	NULL
enhanceosome	NULL
structures	NULL
.	NULL

The	NULL
apparent	NULL
presence	NULL
of	NULL
GATA-1	NULL
in	NULL
the	NULL
IL-2-inducible	NULL
complex	NULL
(	NULL
C4	NULL
)	NULL
was	NULL
surprising	NULL
since	NULL
GATA-1	NULL
has	NULL
only	NULL
been	NULL
5633	NULL
S.John	NULL
,	NULL
C.M.Robbins	NULL
and	NULL
W.J.Leonard	NULL
shown	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
erythroid	NULL
lineage	NULL
.	NULL

We	NULL
have	NULL
not	NULL
detected	NULL
GATA-1	NULL
transcripts	NULL
or	NULL
protein	NULL
in	NULL
preactivated	NULL
PBL	NULL
extracts	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
and	NULL
therefore	NULL
hypothesize	NULL
that	NULL
complex	NULL
C4	NULL
may	NULL
contain	NULL
a	NULL
novel	NULL
protein	NULL
that	NULL
shares	NULL
an	NULL
epitope	NULL
with	NULL
GATA-1	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
EMSAs	NULL
performed	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
COS-7	NULL
cell	NULL
transfectants	NULL
expressing	NULL
murine	NULL
GATA-1	NULL
,	NULL
human	NULL
StatSA	NULL
,	NULL
Stat5B	NULL
and	NULL
Elf-1	NULL
proteins	NULL
(	NULL
each	NULL
alone	NULL
or	NULL
all	NULL
in	NULL
combination	NULL
)	NULL
,	NULL
we	NULL
found	NULL
that	NULL
although	NULL
GATA-1	NULL
could	NULL
bind	NULL
to	NULL
PRRIII	NULL
we	NULL
could	NULL
not	NULL
reconstitute	NULL
complex	NULL
C4	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
reinforcing	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
C4	NULL
may	NULL
contain	NULL
a	NULL
GATA-l-related	NULL
rather	NULL
than	NULL
authentic	NULL
GATA-1	NULL
protein	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
exact	NULL
identity	NULL
of	NULL
the	NULL
protein	NULL
in	NULL
this	NULL
complex	NULL
remains	NULL
unclear	NULL
;	NULL
however	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
its	NULL
binding	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
IL-2	NULL
stimulation	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
human	NULL
IL-2	NULL
response	NULL
element	NULL
has	NULL
evolved	NULL
to	NULL
incorporate	NULL
an	NULL
additional	NULL
level	NULL
of	NULL
control	NULL
as	NULL
compared	NULL
to	NULL
its	NULL
murine	NULL
counterpart	NULL
in	NULL
that	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
contains	NULL
an	NULL
overlapping	NULL
EBS	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
site	NULL
(	NULL
mutant	NULL
affected	NULL
the	NULL
formation	NULL
of	NULL
all	NULL
four	NULL
complexes	NULL
C1-C4	NULL
;	NULL
interestingly	NULL
however	NULL
,	NULL
only	NULL
complex	NULL
C1	NULL
was	NULL
abrogated	NULL
by	NULL
this	NULL
mutation	NULL
although	NULL
all	NULL
four	NULL
complexes	NULL
had	NULL
revealed	NULL
protection	NULL
of	NULL
this	NULL
site	NULL
in	NULL
methylation	NULL
interefence	NULL
analyses	NULL
.	NULL

Since	NULL
mutation	NULL
of	NULL
this	NULL
EBS	NULL
alone	NULL
results	NULL
in	NULL
a	NULL
dramatic	NULL
increase	NULL
in	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-2R	NULL
&	NULL
promoter	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
proteins	NULL
that	NULL
comprise	NULL
complex	NULL
C1	NULL
can	NULL
function	NULL
to	NULL
negatively	NULL
regulate	NULL
IL-2R	NULL
«	NULL
promoter	NULL
activity	NULL
.	NULL

Surprisingly	NULL
however	NULL
,	NULL
a	NULL
related	NULL
mutant	NULL
,	NULL
M1.2	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
simultaneous	NULL
mutation	NULL
of	NULL
this	NULL
EBS	NULL
and	NULL
the	NULL
consensus	NULL
GAS	NULL
motif	NULL
did	NULL
not	NULL
show	NULL
elevated	NULL
basal	NULL
levels	NULL
of	NULL
promoter	NULL
activity	NULL
.	NULL

While	NULL
the	NULL
reason	NULL
for	NULL
this	NULL
difference	NULL
in	NULL
functional	NULL
activities	NULL
between	NULL
M1.1	NULL
and	NULL
M1.2	NULL
is	NULL
unclear	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
although	NULL
mutants	NULL
M1.1	NULL
and	NULL
M1.2	NULL
only	NULL
show	NULL
an	NULL
apparent	NULL
difference	NULL
in	NULL
the	NULL
ability	NULL
to	NULL
form	NULL
complex	NULL
C4	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
occupancy	NULL
of	NULL
these	NULL
two	NULL
mutant	NULL
IL-2Ra	NULL
promoter	NULL
constructs	NULL
may	NULL
be	NULL
different	NULL
from	NULL
that	NULL
detected	NULL
by	NULL
in	NULL
vitro	NULL
gel	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Thus	NULL
the	NULL
precise	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
differences	NULL
in	NULL
the	NULL
activities	NULL
of	NULL
these	NULL
mutants	NULL
awaits	NULL
future	NULL
studies	NULL
aimed	NULL
at	NULL
the	NULL
identification	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
proteins	NULL
contained	NULL
within	NULL
complex	NULL
C1	NULL
and	NULL
a	NULL
more	NULL
detailed	NULL
study	NULL
of	NULL
the	NULL
role	NULL
played	NULL
by	NULL
this	NULL
EBS	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
the	NULL
IL-2R	NULL
«	NULL
promoter	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
IL-2Ra	NULL
promoter	NULL
contains	NULL
multiple	NULL
regulatory	NULL
regions	NULL
which	NULL
together	NULL
orchestrate	NULL
a	NULL
coordinated	NULL
response	NULL
to	NULL
mitogenic	NULL
or	NULL
growth	NULL
factor	NULL
stimulation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
characterized	NULL
in	NULL
detail	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
PRRIII	NULL
and	NULL
shown	NULL
that	NULL
they	NULL
can	NULL
both	NULL
positively	NULL
and	NULL
negatively	NULL
regulate	NULL
IL-2-induced	NULL
transcriptional	NULL
activity	NULL
.	NULL

We	NULL
demonstrated	NULL
previously	NULL
protein-protein	NULL
interactions	NULL
between	NULL
proteins	NULL
binding	NULL
to	NULL
PRRI	NULL
and	NULL
PRRII	NULL
and	NULL
suggested	NULL
that	NULL
IL-2Ra	NULL
transcription	NULL
might	NULL
depend	NULL
on	NULL
the	NULL
formation	NULL
of	NULL
activation-induced	NULL
nucleoprotein	NULL
complexes	NULL
(	NULL
John	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
characterize	NULL
PRRIII	NULL
as	NULL
an	NULL
additional	NULL
important	NULL
regulatory	NULL
element	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
PRRIII	NULL
is	NULL
located	NULL
at	NULL
a	NULL
large	NULL
distance	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
further	NULL
suggests	NULL
that	NULL
DNA	NULL
bending	NULL
or	NULL
looping	NULL
may	NULL
be	NULL
required	NULL
for	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2Ra	NULL
«	NULL
a	NULL
promoter	NULL
.	NULL

It	NULL
will	NULL
be	NULL
important	NULL
to	NULL
elucidate	NULL
how	NULL
the	NULL
signal	NULL
from	NULL
PRRIII	NULL
is	NULL
integrated	NULL
with	NULL
signals	NULL
from	NULL
other	NULL
regions	NULL
of	NULL
the	NULL
promoter	NULL
and	NULL
whether	NULL
5634	NULL
PRRIII	NULL
is	NULL
important	NULL
in	NULL
regulating	NULL
IL-2	NULL
Ra	NULL
promoter	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
other	NULL
signals	NULL
in	NULL
addition	NULL
to	NULL
IL-2	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
culture	NULL
YT	NULL
natural	NULL
killer-like	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/m	NULL
!	NULL

streptomycin	NULL
and	NULL
2	NULL
mM	NULL
glutamine	NULL
.	NULL

Preactivated	NULL
PBLs	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
,	NULL
antibodies	NULL
and	NULL
purified	NULL
protein	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
Dignam	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
kit	NULL
.	NULL

The	NULL
anti-human	NULL
Elf-1	NULL
,	NULL
GATA-1	NULL
,	NULL
GATA-3	NULL
,	NULL
StatSA	NULL
and	NULL
Stat5B	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

EMSAs	NULL
Binding	NULL
reactions	NULL
(	NULL
20	NULL
jil	NULL
)	NULL
contained	NULL
2	NULL
ul	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
proteins	NULL
or	NULL
5-10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBL	NULL
,	NULL
10	NULL
000	NULL
c.p.m	NULL
.	NULL

of	NULL
probe	NULL
(	NULL
0.1-0.2	NULL
ng	NULL
)	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
in	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
1.25	NULL
mM	NULL
DTT	NULL
,	NULL
1.1	NULL
mM	NULL
EDTA	NULL
and	NULL
15	NULL
%	NULL
glycerol	NULL
.	NULL

Following	NULL
incubation	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
analyzed	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
(	NULL
40:1	NULL
acrylamide	NULL
:	NULL
bisacrylamide	NULL
)	NULL
run	NULL
in	NULL
Tris-borate	NULL
buffer	NULL
at	NULL
150	NULL
V	NULL
for	NULL
2.5	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

In	NULL
antibody	NULL
supershift	NULL
assays	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
specific	NULL
antiserum	NULL
was	NULL
preincubated	NULL
with	NULL
proteins	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Probe	NULL
was	NULL
then	NULL
added	NULL
and	NULL
incubations	NULL
continued	NULL
for	NULL
15	NULL
min	NULL
before	NULL
analysis	NULL
on	NULL
gels	NULL
.	NULL

Plasmids	NULL
and	NULL
oligonucleotides	NULL
The	NULL
IL-2R	NULL
@	NULL
promoter	NULL
sequence	NULL
was	NULL
determined	NULL
by	NULL
double-stranded	NULL
DNA	NULL
sequence	NULL
analysis	NULL
using	NULL
Sequenase	NULL
and	NULL
by	NULL
fluorescent	NULL
double-stranded	NULL
DNA	NULL
sequence	NULL
analysis	NULL
using	NULL
an	NULL
Applied	NULL
Biosystems	NULL
Model	NULL
377	NULL
fluorescent	NULL
sequencer	NULL
with	NULL
a	NULL
modified	NULL
ABI	NULL
protocol	NULL
(	NULL
Robbins	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

All	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
HindIII	NULL
(	NULL
5	NULL
'	NULL
)	NULL
and	NULL
BamHI	NULL
(	NULL
3	NULL
'	NULL
)	NULL
ends	NULL
.	NULL

The	NULL
double-stranded	NULL
PRRIII	NULL
oligonucleotide	NULL
(	NULL
-3780	NULL
to	NULL
-3703	NULL
,	NULL
see	NULL
Figure	NULL
1A	NULL
and	NULL
B	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
pBLCAT2	NULL
(	NULL
Luckow	NULL
and	NULL
Schutz	NULL
,	NULL
1987	NULL
)	NULL
and	NULL
the	NULL
DNA	NULL
sequence	NULL
verified	NULL
.	NULL

The	NULL
Bg/II-Psfl	NULL
IL-2Ra	NULL
-4103	NULL
to	NULL
+109	NULL
fragment	NULL
was	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
in	NULL
pUC13	NULL
.	NULL

The	NULL
control	NULL
plasmid	NULL
,	NULL
pBLCAT3	NULL
was	NULL
a	NULL
promoterless	NULL
plasmid	NULL
that	NULL
contained	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Luckow	NULL
and	NULL
Schutz	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
IL-2Ra	NULL
-4103	NULL
to	NULL
+109	NULL
promoter	NULL
mutants	NULL
were	NULL
constructed	NULL
using	NULL
the	NULL
MORPH	NULL
site	NULL
specific	NULL
DNA	NULL
mutagenesis	NULL
kit	NULL
(	NULL
5	NULL
Prime-3	NULL
Prime	NULL
,	NULL
Inc.	NULL
)	NULL
The	NULL
DNA	NULL
sequence	NULL
of	NULL
each	NULL
mutant	NULL
was	NULL
confirmed	NULL
.	NULL

The	NULL
Elf-1	NULL
expression	NULL
vector	NULL
,	NULL
peDNA3-Elf-1	NULL
,	NULL
was	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
EcoRV-Xhol	NULL
Elf-l	NULL
cDNA	NULL
fragment	NULL
from	NULL
pcDElf-1	NULL
(	NULL
Thompson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
into	NULL
peDNA3	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
CAT	NULL
assays	NULL
YT	NULL
cells	NULL
were	NULL
transfected	NULL
using	NULL
DEAE-dextran	NULL
(	NULL
Sompayrac	NULL
and	NULL
Danna	NULL
,	NULL
1981	NULL
)	NULL
,	NULL
12	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
from	NULL
IL-2Ra	NULL
&	NULL
promoter	NULL
constructs	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
PRRIII-TKCAT	NULL
reporter	NULL
construct	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
for	NULL
24-30	NULL
h	NULL
,	NULL
stimulated	NULL
overnight	NULL
with	NULL
2	NULL
nM	NULL
IL-2	NULL
,	NULL
and	NULL
cell	NULL
extracts	NULL
prepared	NULL
by	NULL
three	NULL
cycles	NULL
of	NULL
freeze-thawing	NULL
in	NULL
0.25	NULL
M	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
.	NULL

Extracts	NULL
were	NULL
clarified	NULL
at	NULL
65°C	NULL
for	NULL
10	NULL
min	NULL
followed	NULL
by	NULL
centrifugation	NULL
.	NULL

Protein	NULL
concentrations	NULL
of	NULL
the	NULL
supernatants	NULL
were	NULL
determined	NULL
,	NULL
and	NULL
equivalent	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
.	NULL

Acetylated	NULL
forms	NULL
of	NULL
chloramphenicol	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
layer	NULL
chromatography	NULL
and	NULL
quantitated	NULL
using	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
PhosphorImager	NULL
.	NULL

Methylation	NULL
interference	NULL
assays	NULL
PRRIII-TKCAT	NULL
was	NULL
linearized	NULL
at	NULL
either	NULL
end	NULL
with	NULL
HindIII	NULL
or	NULL
BamHI	NULL
and	NULL
end-labeled	NULL
with	NULL
[	NULL
&	NULL
-*P	NULL
]	NULL
JdATP	NULL
and	NULL
[	NULL
«	NULL
-	NULL
>	NULL
``	NULL
P	NULL
]	NULL
dGTP	NULL
(	NULL
both	NULL
>	NULL
3000	NULL
Ci/mmol	NULL
;	NULL
Amersham	NULL
)	NULL
by	NULL
a	NULL
fill-in	NULL
reaction	NULL
with	NULL
Klenow	NULL
enzyme	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
released	NULL
by	NULL
a	NULL
second	NULL
digestion	NULL
with	NULL
BamHI	NULL
or	NULL
HindIII	NULL
,	NULL
as	NULL
appropriate	NULL
,	NULL
and	NULL
purified	NULL
on	NULL
non-denaturing	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Typically	NULL
,	NULL
0.5X10°	NULL
c.p.m	NULL
.	NULL

of	NULL
end-labeled	NULL
probe	NULL
and	NULL
25	NULL
pug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
in	NULL
each	NULL
binding	NULL
reaction	NULL
.	NULL

Methylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Baldwin	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
Mike	NULL
Erdos	NULL
and	NULL
Ryan	NULL
Child	NULL
for	NULL
assistance	NULL
with	NULL
sequence	NULL
analysis	NULL
and	NULL
Drs	NULL
Jian-Xin	NULL
Lin	NULL
and	NULL
Judy	NULL
Mietz	NULL
for	NULL
critical	NULL
comments	NULL
.	NULL

References	NULL
Algarte.M..	NULL
Lecine	NULL
,	NULL
P.	NULL
,	NULL
Costello.R..	NULL
Plet.A..	NULL
Olive.D	NULL
.	NULL

and	NULL
Imbert.J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
In	NULL
vivo	NULL
regulation	NULL
of	NULL
interleukin-2	NULL
receptor	NULL
®	NULL
gene	NULL
transcription	NULL
by	NULL
the	NULL
coordinated	NULL
binding	NULL
of	NULL
constitutive	NULL
and	NULL
inducible	NULL
factors	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
5060-5072	NULL
.	NULL

Baldwin	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Methylation	NULL
interference	NULL
assay	NULL
for	NULL
analysis	NULL
of	NULL
DNA-protein	NULL
interactions	NULL
.	NULL

In	NULL
Ausubel.F.M	NULL
.	NULL

,	NULL
Brent.R	NULL
.	NULL

,	NULL
Kingston.R.E	NULL
.	NULL

,	NULL
Moore.D.D..	NULL
Seidman.J.G	NULL
.	NULL

,	NULL
Smith	NULL
,	NULL
J.A	NULL
.	NULL

and	NULL
StruhLK	NULL
.	NULL

(	NULL
eds	NULL
)	NULL
,	NULL
Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
,	NULL
Vol	NULL
.	NULL

2	NULL
,	NULL
pp.12.3.1-12.3.4	NULL
.	NULL

Ballard.D.W	NULL
.	NULL

,	NULL
Bohnlein.E	NULL
.	NULL

,	NULL
HoffmanJ.A..	NULL
Bogerd	NULL
,	NULL
H.P..	NULL
Dixon	NULL
,	NULL
E.P	NULL
.	NULL

,	NULL
Franza.B.R	NULL
.	NULL

and	NULL
Greene	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
¢	NULL
chain	NULL
gene	NULL
:	NULL
regulatory	NULL
role	NULL
for	NULL
DNA-protein	NULL
interactions	NULL
flanking	NULL
the	NULL
B	NULL
enhancer	NULL
.	NULL

New	NULL
Bio/	NULL
.	NULL

,	NULL
1	NULL
,	NULL
83-92	NULL
.	NULL

Bohnlein.E..	NULL
Lowenthal.J.W	NULL
.	NULL

,	NULL
Siekevitz.M	NULL
.	NULL

,	NULL
Ballard.D.W..	NULL
Franza	NULL
,	NULL
B.R	NULL
.	NULL

and	NULL
Greene	NULL
.	NULL

W.C.	NULL
(	NULL
1988	NULL
)	NULL
The	NULL
same	NULL
inducible	NULL
nuclear	NULL
proteins	NULL
regulates	NULL
mitogen	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
alpha	NULL
gene	NULL
and	NULL
type	NULL
1	NULL
HIV	NULL
.	NULL

Cell	NULL
,	NULL
53	NULL
.	NULL

827-836	NULL
.	NULL

Cross.S.L..	NULL
Feinberg	NULL
.	NULL

M.B	NULL
.	NULL

,	NULL
Wolf	NULL
,	NULL
J.B.	NULL
,	NULL
Holbrook.N.J..	NULL
Wong-StaaL.F	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

W.J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Regulation	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
receptor	NULL
&	NULL
chain	NULL
gene	NULL
promoter	NULL
:	NULL
activation	NULL
of	NULL
a	NULL
nonfunctional	NULL
promoter	NULL
by	NULL
the	NULL
transactivator	NULL
gene	NULL
of	NULL
HTLV-I	NULL
.	NULL

Cell	NULL
,	NULL
49	NULL
,	NULL
47-56	NULL
.	NULL

Cross.S.L..	NULL
Halden.N.F..	NULL
Lenardo.M.J	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Functionally	NULL
distinct	NULL
NF-xB	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
Igx	NULL
and	NULL
IL-2	NULL
receptor	NULL
&	NULL
chain	NULL
genes	NULL
.	NULL

Science	NULL
,	NULL
244	NULL
,	NULL
466-469	NULL
.	NULL

Depper.J.M..	NULL
Leonard	NULL
.	NULL

W.J	NULL
.	NULL

,	NULL
Drogula	NULL
,	NULL
C..	NULL
Kronke	NULL
.	NULL

M..	NULL
Waldmann.T.A	NULL
.	NULL

and	NULL
Greene	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
augments	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
82	NULL
,	NULL
4230-4234	NULL
.	NULL

Dignam.J.D..	NULL
Lebovitz.R.M	NULL
.	NULL

and	NULL
RoederR.G	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
1475-1489	NULL
.	NULL

Du	NULL
.	NULL

W.	NULL
,	NULL
Thanos.D	NULL
.	NULL

and	NULL
Maniatis.T	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mechanisms	NULL
of	NULL
transcriptional	NULL
synergism	NULL
between	NULL
distinct	NULL
virus-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell/	NULL
,	NULL
74	NULL
.	NULL

887-898	NULL
.	NULL

Falvo.J	NULL
.	NULL

V.	NULL
,	NULL
Thanos.D	NULL
.	NULL

and	NULL
Maniatis	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Reversal	NULL
of	NULL
intrinsic	NULL
DNA	NULL
bends	NULL
in	NULL
the	NULL
IFNB	NULL
gene	NULL
enhancer	NULL
by	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
architectural	NULL
protein	NULL
HMG-I	NULL
(	NULL
Y	NULL
)	NULL
Cell	NULL
,	NULL
83	NULL
.	NULL

1101-1111	NULL
.	NULL

FujiiH	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Activation	NULL
of	NULL
Stats	NULL
by	NULL
interleukin	NULL
2	NULL
requires	NULL
a	NULL
carboxyl-terminal	NULL
region	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
B	NULL
chain	NULL
but	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
the	NULL
proliferative	NULL
signal	NULL
transmission	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
.	NULL

5482-5486	NULL
.	NULL

Gaffen	NULL
,	NULL
S.L..	NULL
Lai.S.Y	NULL
.	NULL

,	NULL
Xu	NULL
,	NULL
.W	NULL
.	NULL

,	NULL
Gouilleux.F	NULL
.	NULL

,	NULL
Groner.B..	NULL
Goldsmith.M.A	NULL
.	NULL

and	NULL
Greene	NULL
.	NULL

W.C.	NULL
(	NULL
1995	NULL
)	NULL
Signaling	NULL
through	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
B	NULL
chain	NULL
activates	NULL
a	NULL
STAT-S5-like	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
.	NULL

7192-7196	NULL
.	NULL

Gilmour.K..	NULL
Pine.R	NULL
.	NULL

and	NULL
Reich	NULL
,	NULL
.N.C	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Interleukin	NULL
2	NULL
activates	NULL
STATS	NULL
transcription	NULL
factor	NULL
(	NULL
mammary	NULL
gland	NULL
factor	NULL
)	NULL
and	NULL
specific	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
10772-10776	NULL
.	NULL

Ho.L-C..	NULL
Vorhees	NULL
,	NULL
P..	NULL
Marin.N	NULL
.	NULL

,	NULL
Oakley.B.K..	NULL
Tsai.S.-F.	NULL
,	NULL
Orkin	NULL
,	NULL
.S.H	NULL
.	NULL

and	NULL
Leiden.J.M	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Human	NULL
GATA-3	NULL
:	NULL
a	NULL
lineage-restricted	NULL
transcription	NULL
factor	NULL
that	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
a	NULL
gene	NULL
.	NULL

EMBO	NULL
J..	NULL
10	NULL
,	NULL
1187-1192	NULL
.	NULL

Hou.J	NULL
.	NULL

,	NULL
Schindler.U	NULL
.	NULL

,	NULL
Henzel	NULL
,	NULL
W.J	NULL
.	NULL

,	NULL
Wong.S.C	NULL
.	NULL

and	NULL
McKnight.S.L	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Identification	NULL
and	NULL
purification	NULL
of	NULL
human	NULL
Stat	NULL
proteins	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
interleukin-2	NULL
.	NULL

/mmunity	NULL
.	NULL

2	NULL
,	NULL
321-329	NULL
.	NULL

Inoue.J..	NULL
Seiki.M..	NULL
Taniguchi.T	NULL
.	NULL

,	NULL
Tsuru	NULL
.	NULL

$	NULL
.	NULL

and	NULL
Yoshida.M	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Induction	NULL
of	NULL
interleukin-2	NULL
receptor	NULL
gene	NULL
expression	NULL
by	NULL
p40x	NULL
encoded	NULL
human	NULL
T-cell	NULL
leukmia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
5	NULL
.	NULL

2883-2888	NULL
.	NULL

John.S..	NULL
Reeves	NULL
,	NULL
R.B	NULL
.	NULL

,	NULL
Lin.J.-X	NULL
.	NULL

,	NULL
Child.R	NULL
.	NULL

,	NULL
Leiden.J.M..	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

W.J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Regulation	NULL
of	NULL
cell-type-specific	NULL
interleukin-2	NULL
receptor	NULL
(	NULL
-chain	NULL
gene	NULL
expression	NULL
:	NULL
potential	NULL
role	NULL
of	NULL
physical	NULL
interactions	NULL
between	NULL
Elf-1	NULL
.	NULL

HMG-I	NULL
(	NULL
Y	NULL
)	NULL
.	NULL

and	NULL
NF-xB	NULL
family	NULL
proteins	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
.	NULL

1786-1796	NULL
.	NULL

John.S..	NULL
Marais.R..	NULL
Child.R..	NULL
Light.Y	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Importance	NULL
of	NULL
low	NULL
affinity	NULL
Elf-1	NULL
sites	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
lymphoid	NULL
specific	NULL
inducible	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
183	NULL
.	NULL

743-750	NULL
.	NULL

Leonard	NULL
.	NULL

W.J..	NULL
Noguchi.M	NULL
.	NULL

,	NULL
Russell	NULL
,	NULL
S.M	NULL
.	NULL

and	NULL
McBride.O.W	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
molecular	NULL
basis	NULL
of	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
:	NULL
the	NULL
role	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
as	NULL
a	NULL
common	NULL
y	NULL
chain	NULL
.	NULL

y..	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
138	NULL
,	NULL
61-86	NULL
.	NULL

Leung.K	NULL
.	NULL

and	NULL
Nabel.G.J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
HTLV-L	NULL
transactivator	NULL
induces	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
through	NULL
an	NULL
NF-KB	NULL
like	NULL
factor	NULL
.	NULL

Nature	NULL
,	NULL
333	NULL
.	NULL

776-778	NULL
.	NULL

Lin.B.B..	NULL
Cross.S.L..	NULL
Halden.N.F..	NULL
Roman	NULL
,	NULL
D.G..	NULL
Toledano.M.B	NULL
.	NULL

and	NULL
Leonard.W.J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Delineation	NULL
of	NULL
an	NULL
enhancer	NULL
like	NULL
positive	NULL
IL-2	NULL
response	NULL
element	NULL
in	NULL
human	NULL
IL-2Ra	NULL
promoter	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
-chain	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
.	NULL

850-853	NULL
.	NULL

Lin	NULL
,	NULL
J.-X	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
The	NULL
role	NULL
of	NULL
shared	NULL
receptor	NULL
motifs	NULL
and	NULL
common	NULL
Stat	NULL
proteins	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
cytokine	NULL
pleiotropy	NULL
and	NULL
redundancy	NULL
by	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-13	NULL
.	NULL

and	NULL
IL-15	NULL
.	NULL

Immunity	NULL
,	NULL
2	NULL
.	NULL

331-339	NULL
.	NULL

Lin.J.-X..	NULL
Mietz.J	NULL
.	NULL

,	NULL
Modi.W.S	NULL
.	NULL

,	NULL
John.S	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

W.J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Cloning	NULL
of	NULL
human	NULL
StatSB	NULL
:	NULL
Reconstitution	NULL
of	NULL
IL-2-induced	NULL
human	NULL
StatSA	NULL
and	NULL
Stat5B	NULL
binding	NULL
activity	NULL
in	NULL
COS-7	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem..	NULL
271	NULL
.	NULL

10738-10744	NULL
.	NULL

Lowenthal.J.W..	NULL
Ballard.D.W	NULL
.	NULL

,	NULL
Bohnlein.E	NULL
.	NULL

and	NULL
Greene.W.C	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
induces	NULL
proteins	NULL
that	NULL
bind	NULL
specifically	NULL
to	NULL
«	NULL
B-like	NULL
enhancer	NULL
elements	NULL
and	NULL
regulator	NULL
interleukin	NULL
2	NULL
receptor	NULL
-chain	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
2331-2335	NULL
.	NULL

Luckow.B	NULL
.	NULL

and	NULL
Schutz.G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res..	NULL
15	NULL
,	NULL
251-256	NULL
.	NULL

Magis.W	NULL
.	NULL

and	NULL
Martin.D.LK	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
HMG-I	NULL
binds	NULL
to	NULL
GATA	NULL
motifs	NULL
:	NULL
Implications	NULL
for	NULL
an	NULL
HPFH	NULL
syndrome	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
214	NULL
,	NULL
927-933	NULL
.	NULL

Maruyama	NULL
.	NULL

M..	NULL
-	NULL
Shibuya.H..	NULL
Harada	NULL
,	NULL
H..	NULL
-	NULL
Hatakeyama.M..	NULL
-	NULL
Seiki.M..	NULL
Fujita	NULL
,	NULL
T..	NULL
Inoue.J..	NULL
Yoshida	NULL
.	NULL

M.	NULL
and	NULL
Taniguchi.T	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Evidence	NULL
for	NULL
aberrant	NULL
activation	NULL
of	NULL
interleukin-2	NULL
autocrine	NULL
loop	NULL
by	NULL
HTLV-I	NULL
encoded	NULL
p40®	NULL
and	NULL
T3/Ti	NULL
complex	NULL
triggering	NULL
.	NULL

Cell	NULL
.	NULL

48	NULL
,	NULL
343-350	NULL
.	NULL

Nielsen.M	NULL
.	NULL

,	NULL
Svejgaard.A..	NULL
Skov.S	NULL
.	NULL

and	NULL
Odum.N	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Interleukin-2	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
Stat3	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
24	NULL
.	NULL

3082-3086	NULL
.	NULL

Robbins	NULL
,	NULL
C.M..	NULL
Hsu.E	NULL
.	NULL

and	NULL
Gilleret.P.M	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Sequencing	NULL
homopolymer	NULL
tracts	NULL
and	NULL
repetitive	NULL
elements	NULL
.	NULL

Biotechniques	NULL
.	NULL

20	NULL
,	NULL
862-868	NULL
.	NULL

Roman.D.G..	NULL
Toledano.M.B	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

W.J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Spl	NULL
represses	NULL
the	NULL
IL-2	NULL
receptor	NULL
&	NULL
chain	NULL
gene	NULL
expression	NULL
.	NULL

New	NULL
Biol..	NULL
2	NULL
.	NULL

642-647	NULL
.	NULL

Siegel.J.P	NULL
.	NULL

Sharon.M..	NULL
Smith.PL	NULL
.	NULL

and	NULL
Leonard	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
The	NULL
interleukin-2	NULL
receptor	NULL
B	NULL
chain	NULL
(	NULL
p70	NULL
)	NULL
:	NULL
role	NULL
in	NULL
mediating	NULL
signals	NULL
for	NULL
LAK	NULL
.	NULL

NK	NULL
.	NULL

and	NULL
proliferative	NULL
activities	NULL
.	NULL

Science	NULL
.	NULL

238	NULL
,	NULL
75-78	NULL
.	NULL

Siekevitz.M..	NULL
-	NULL
Feinberg	NULL
.	NULL

Holbrook.N.K..	NULL
Wong-Staal.F	NULL
.	NULL

-	NULL
and	NULL
Greene.W.C	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Activation	NULL
of	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
(	NULL
Tac	NULL
)	NULL
promoter	NULL
expression	NULL
by	NULL
the	NULL
transactivator	NULL
(	NULL
tat	NULL
)	NULL
gene	NULL
product	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
,	NULL
type	NULL
I.	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
.	NULL

5389-5393	NULL
.	NULL

Sompayrac.L.M	NULL
.	NULL

and	NULL
Danna.K.J	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Efficient	NULL
infection	NULL
of	NULL
monkey	NULL
cells	NULL
with	NULL
DNA	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
.	NULL

78	NULL
.	NULL

7575-1578	NULL
.	NULL

Sperisen	NULL
,	NULL
P.	NULL
,	NULL
Wang.S.M..	NULL
Soldaini.E	NULL
.	NULL

,	NULL
Pla	NULL
,	NULL
M..	NULL
Rusterholz.C	NULL
.	NULL

,	NULL
Bucher.P..	NULL
Corthesy.P..	NULL
Reichenbach.P	NULL
.	NULL

and	NULL
Nabholz.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Mouse	NULL
interleukin-2	NULL
receptor	NULL
o	NULL
gene	NULL
expression	NULL
.	NULL

Interleukin-1	NULL
and	NULL
interleukin-2	NULL
control	NULL
transcription	NULL
via	NULL
distinct	NULL
cis-acting	NULL
elements	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem..	NULL
270	NULL
.	NULL

10743-10753	NULL
.	NULL

Sugamura.K..	NULL
Asao.H..	NULL
Kondo.M..	NULL
Tanaka.N..	NULL
Ishii.N..	NULL
Nakamura.M	NULL
.	NULL

and	NULL
Takeshita.T	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
The	NULL
common	NULL
y-chain	NULL
for	NULL
multiple	NULL
cytokine	NULL
receptors	NULL
.	NULL

Adv	NULL
.	NULL

Immunol..	NULL
59	NULL
,	NULL
225-277	NULL
.	NULL

Taniguchi.T	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cytokine	NULL
signaling	NULL
through	NULL
nonreceptor	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
.	NULL

268	NULL
,	NULL
251-255	NULL
.	NULL

Thanos.D	NULL
.	NULL

and	NULL
Maniatis.T	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
The	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
is	NULL
required	NULL
for	NULL
NF-xB-dependent	NULL
virus	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
IFN-B	NULL
gene	NULL
.	NULL

Cell	NULL
,	NULL
71	NULL
.	NULL

777-789	NULL
.	NULL

Thanos.D	NULL
.	NULL

and	NULL
Maniatis.T	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Virus	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
IFNB	NULL
gene	NULL
expression	NULL
requires	NULL
the	NULL
assembly	NULL
of	NULL
an	NULL
enhanceosome	NULL
.	NULL

Cell	NULL
,	NULL
83	NULL
.	NULL

1091-1100	NULL
.	NULL

Thompson.C.B	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cis	NULL
acting	NULL
sequences	NULL
required	NULL
for	NULL
inducible	NULL
interleukin-2	NULL
enhancer	NULL
function	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol..	NULL
12	NULL
.	NULL

10343-1053	NULL
.	NULL

Toledano.M.B	NULL
.	NULL

,	NULL
Roman.D.G..	NULL
Halden.N.F	NULL
.	NULL

,	NULL
Lin.B.B	NULL
.	NULL

and	NULL
Leonard.W.J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
The	NULL
same	NULL
target	NULL
sequences	NULL
are	NULL
differentially	NULL
important	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
o-chain	NULL
gene	NULL
in	NULL
two	NULL
distinct	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
.	NULL

87	NULL
,	NULL
1830-1834	NULL
.	NULL

Wakao.H..	NULL
Harada.N..	NULL
Kitamura.T..	NULL
Mui	NULL
,	NULL
.A.L	NULL
.	NULL

and	NULL
Miyajima.A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Interleukin	NULL
2	NULL
and	NULL
erythropoietin	NULL
activate	NULL
STATS/MGF	NULL
via	NULL
distinct	NULL
pathways	NULL
.	NULL

EMBO	NULL
J..	NULL
14	NULL
,	NULL
2527-2535	NULL
.	NULL

Weiss.M.J	NULL
.	NULL

and	NULL
Orkin.S.H	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
GATA	NULL
transcription	NULL
factors	NULL
:	NULL
Key	NULL
regulators	NULL
of	NULL
hematopoiesis	NULL
.	NULL

Exp	NULL
.	NULL

Hematol..	NULL
23	NULL
.	NULL

99-107	NULL
.	NULL

Willerford.D.M..	NULL
Chen.J..	NULL
Ferry.J.A	NULL
.	NULL

,	NULL
Davidson.L	NULL
.	NULL

,	NULL
Ma.A	NULL
.	NULL

and	NULL
AILEW	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Interleukin-2	NULL
receptor	NULL
o	NULL
chain	NULL
regulates	NULL
the	NULL
size	NULL
and	NULL
content	NULL
of	NULL
the	NULL
peripheral	NULL
lymphoid	NULL
compartment	NULL
.	NULL

/mmunity	NULL
,	NULL
3	NULL
,	NULL
521-530	NULL
.	NULL

Received	NULL
on	NULL
May	NULL
23	NULL
,	NULL
1996	NULL
;	NULL
revised	NULL
on	NULL
July	NULL
12	NULL
,	NULL
1996	NULL
5635	NULL

